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ABSTRACT OF THE DISSERTATION 
THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON BIOMARKERS OF 
OXIDATIVE STRESS AND GLYCEMIC STATUS IN ADULTS WITH TYPE 2 
DIABETES 
by 
Sahar Ajabshir 
Florida International University, 2018 
Miami, Florida 
Professor Fatma G. Huffman, Major Professor 
The aim of the present study was to assess the effect of 4000 IU and 6000 IU of daily 
vitamin D3 supplementation for 3 months and 6 months on 8-hydroxy-2`-
deoxyguanosine (8-OHdG) and glycated albumin (GA%) among a group of individuals 
with T2D and hypovitaminosis D. Furthermore, this study investigated the association 
between dietary inflammatory index (DII), C-reactive protein (CRP), 8-OHdG, 
hemoglobin A1C (HbA1c), GA% and insulin. Ninety participants were recruited by 
community outreach and were screened. Sixty-eight participants met the inclusion criteria 
were enrolled and completed the study.  DII for each individuals was calculated based on 
the values obtained from a validated food frequency questionnaire. Measurements of 
variables were conducted at baseline, after 3 months and after 6 months of 
supplementation. Serum CRP, 8-OHdg, GA%, HbA1c and insulin were measured by 
enzymatic immunoassay methods. Mixed model was used to compare treatment groups. 
Covariates in the adjusted model included age, gender, body mass index (BMI), insulin, 
HbA1c, years with type 2 diabetes, perceived stress, physical activity, and sun exposure. 
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Mean age was 54.94 ± 7.93 years. A multivariable linear regression model adjusted for 
age, gender, waist circumference, and fasting plasma glucose was used to test for the 
linear trend between DII and CRP, 8-OHdG, GA% and insulin. The unadjusted model 
showed no significant associations between quartiles of DII, CRP, HbA1c and GA%.  A 
significant inverse association was observed between the fourth DII quartile and insulin level 
(p=0.030). There was a significant association between SBP and DII in Q4 (p=0.029). The 
unadjusted mean ± SD for 8-OHdG levels at baseline, after 3 and 6 months were 8068.94 
± 2158.13 pg/mL, 9462.22 ± 2403.89 pg/mL, and 7412.69 ± 2031.68 pg/mL, 
respectively. The unadjusted mixed model showed no difference between the 4000 and 
6000 IU groups regarding the oxidative stress and GA%. Interactions between time and 
treatment were not significant. The model showed a statistically significant difference in 
8-OHdG level between baseline and 3 months (P<0.001), 3 months and 6 months 
(P<0.001), and baseline and 6 months (P=0.016). The unadjusted mean ± SD for GA% at 
baseline, 3 months and 6 months were 4.69 ± 1.7, 4.13 ± 1.09, and 4.42 ± 1.23, 
respectively. Unadjusted pairwise comparisons between GA% were a statistically 
significant from baseline to 3 months (P=0.015), and from 3 months to 6 months 
(P=0.039), but not from baseline to 6 months (P= 0.488). The results of the present study 
showed daily oral supplementation with higher doses of vitamin D for 6 months may 
have beneficial effects on oxidative stress and glycemic status among a group of 
individuals with type 2 diabetes and vitamin D deficiency/insufficiency. Furthermore, 
pro-inflammatory dietary patterns may be associated with increased risk of 
hyperinsulinemia and hypertension among individuals with T2D and hypovitaminosis D.  
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CHAPTER I: INTRODUCTION 
Diabetes mellitus is ranked as the seventh leading cause of death in the United 
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for 
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S 
population) were diagnosed with diabetes while more than 8 million cases were 
undiagnosed (2). As estimated by the American Diabetes Association in 2013, the total 
direct and indirect costs of diabetes in the U.S. were $245 billion in 2012. Individuals 
with diabetes had 2.3 times more medical expenditures compared to individuals without 
diabetes (3). Native Americans had the highest rates of diagnosed diabetes (15.9%) 
among all race/ethnic groups aged 20 years and older, followed by African Americans 
(13.2%) and Hispanics (12.8%) (3). Type 2 diabetes accounts for 90-95% of all 
diagnosed diabetes cases among adults. Insulin resistance and pancreatic Beta cell 
dysfunction are the major pathophysiological abnormalities that lead to type 2 diabetes 
pathogenesis and progression (4).  
Insulin is a peptide hormone that unlocks the cells to absorb glucose from the 
bloodstream and inhibits gluconeogenesis by the liver. Pancreatic Beta cells are 
responsible for insulin production and secretion. Both decline in insulin sensitivity 
(insulin resistance) and insufficient insulin production result in accumulation of excess 
glucose in blood stream and starvation of the cells for glucose, which can lead to several 
organ or system damages. 
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Type 2 diabetes and inflammation  
Insulin resistance and hyperglycemia are linked to systemic inflammation (5). 
Inflammation is a defense mechanism of the innate immunity. As evidenced by a 9-year 
case-cohort study of 10,275 adults, systemic inflammation precedes diabetes and low 
grade inflammation plays a critical intermediary role in diabetogenesis (6). Accumulating 
evidence suggest that type 2 diabetes is a condition of innate immune system and it may 
be the result of long-term activation of an acute phase cytokine-mediated response of the 
innate immune system (7). Although this acute phase reaction of the innate immune 
system is initially stimulated to maintain homeostasis in response to environmental 
stressors, it is suggested that the sustained activation of this mechanism may lead to 
pathogenesis of many chronic inflammatory conditions such as type 2 diabetes (7). In this 
process stressors, such as age, over-nutrition, physical inactivity, visceral adiposity and 
oxygen metabolites stimulate the innate immune system such as adipose tissue 
macrophages and monocytes to produce and release pro-inflammatory cytokines like 
interleukin (IL)-1, IL-6, IL-18 and tumor necrosis factor-alpha (TNF-α) (8). Elevated 
levels of pro-inflammatory cytokines elicit the liver to synthesize the acute phase 
proteins, such as C-reactive protein (CRP), (8) while inducing dyslipidemia [increased 
low density lipoproteins (LDL) and decreased high density lipoproteins (HDL)] by 
hepatocytes (8). In addition, it is suggested that augmented cytokine levels elicit β-cell 
apoptosis and result in β-cell dysfunction (9). Beside their effects on liver and pancreas, 
pro-inflammatory cytokines stimulate the brain to release adrenocorticotropic hormone 
which results in increased cortisol level (8). Cortisol is a glucocorticoid and hence is a 
functional antagonist of insulin. While insulin diminishes hepatic gluconeogenesis, 
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cortisol promotes gluconeogenesis and impedes the glucose uptake by insulin (10). 
Cortisol directly suppresses the insulin release by the pancreatic β cells (10). Increased 
cortisol is linked to insulin resistance, glucose intolerance and central obesity (11).  
Systemic inflammation has been linked to oxidative stress (12). Increased ROS 
production and impaired oxidative balance result in activation of nuclear factor κB (NF-
κB) which plays a critical regulatory role in immunity and inflammatory responses (13). 
NF-κB regulates the expression of a variety of genes such as growth factors and pro-
inflammatory cytokines such as IL-1β and TNF-α. NF-κB enhances a signaling cascade 
which leads to sustained production of ROS and causes low grade inflammation (14). As 
mentioned earlier, continued production of pro-inflammatory cytokines results in an 
acute phase response by the innate immunity and lead to β cell apoptosis and dysfunction. 
This process diminishes the ability of the pancreas to produce and release insulin and thus 
contributes to type 2 diabetogenesis. 
Nutrition plays a critical role in systemic inflammation regulation (15). It has 
been shown that dietary patterns affect pro-inflammatory and anti-inflammatory 
cytokines` balance and therefore enhance the risk of developing inflammatory diseases 
(16). A comprehensive review of observational and prospective studies along with 
randomized controlled trials suggested an anti-inflammatory property for Mediterranean 
dietary pattern (higher consumption of fruits and vegetables, unrefined carbohydrates, 
and fish, moderate consumption of dairy products and wine, and low consumption of 
non-fish meat) (17), compared to Western diet (higher consumption of refined 
carbohydrates, saturated fat, and red meat) (18). Consumption of antioxidant vitamins, 
such as vitamin C, E, and β-Carotene, and polyunsaturated fatty acids (PUFA), such as 
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Omega-3 fatty acids, have been linked to lower systemic inflammation (19), while higher 
intakes of total and saturated fat have been associated with higher systemic inflammation 
(20-21).  
Dietary inflammatory index 
Dietary Inflammatory Index (DII) is a comprehensive literature-derived tool first 
developed by Caviccia et al. (22) in 2009 to assess the inflammatory potential of each 
individual's diet. Out of 2700 screened articles published from 1950 to 2007, 929 were 
considered for developing the algorithm to formulate DII. The objective of this project 
was to develop a methodology which could quantify dietary intake on a spectrum of 
maximally anti-inflammatory to maximally pro-inflammatory Caviccia at al. (22) 
validated the DII scores against CRP. The results of the validation study showed a 
significant relationship between DII, as a categorical variable, and CRP. Later in 2013, 
DII was updated by Shivappa et al. (23). The updated DII, is based on 1943 articles , out 
of 6500 screened, published in 2010-2013 in regards to the effect of diet on 6 
inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). The updated DII 
include forty-five pro-inflammatory and anti-inflammatory food parameters, compared to 
forty-two in the initial DII. The food parameters include: alcohol, vitamin B12, vitamin 
B6, β-Caroten, caffeine, carbohydrate, cholesterol, energy, eugenol, total fat, fibre, folic 
acid, garlic, ginger, iron, magnesium, monounsaturated fatty acids (MUFA), niacin, n-3 
fatty acids, n-6 fatty acids, onion, protein, PUFA,  riboflavin, saffron, saturated fat, 
selenium, thiamin, trans fat, tumeric, vitamin A, vitamin C, vitamin D, vitamin E, zinc, 
green/black tea, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins, isoflavones, 
pepper, thyme/oregano, rosemary. After fitting the DII to eleven dietary intake data sets 
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from across the world, the globally adjusted scores ranged from +7.98 (maximally pro-
inflammatory) to -8.87 (maximally anti-inflammatory). High DII values (pro-
inflammatory diet) have been linked to low grade inflammation and insulin resistance 
(24), metabolic syndrome (25), cardiovascular diseases (26), colorectal cancer (27-28), 
pancreatic cancer (29), gastric cancer (30), and ovarian cancer (31). 
Type 2 diabetes and oxidative stress 
Oxidative stress is caused by an imbalance between oxygen metabolites 
production and ability of the endogenous and exogenous antioxidant networks to 
neutralize them (32). Reactive oxygen species (ROS), such as superoxide anion (O2
−), 
hydrogen peroxide (H2O2), hydroxyl radical (OH
°) and peroxynitrite (OONO−), have one 
or more unpaired electrons and are highly reactive (33). ROS may attack other molecules 
to take an electron from them and stabilize (34). They can damage proteins, lipids and 
DNA. These oxidized biomolecules may trigger further oxidizing chain reactions that 
may result in production of new free radicals (34-35). Oxidative stress plays a pivotal 
role in systemic inflammation, type 2 diabetes development and its related complications 
(36). Although ROS production is one of the primary defense mechanisms, increased 
ROS production may result in impaired oxidative balance which leads to activation of 
nuclear factor κB (NF-κB). NF-κB plays a critical regulatory role in immunity and 
inflammatory responses (35). NF-κB regulates the expression of a variety of genes such 
as growth factors and pro-inflammatory cytokines and enhances a signaling cascade 
which leads to sustained production of ROS and causing low grade inflammation (37). 
Continued production of pro-inflammatory cytokines results in an acute phase response 
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by the innate immunity and lead to pancreatic β cell apoptosis and dysfunction. This 
process diminishes the ability of the pancreas to produce and release insulin and thus 
causes type 2 diabetes.  
ROS induced oxidation of guanine residues of DNA can damage the DNA strands 
and produce 8-hydroxyguanosine (8-OHdG) (38). Several studies had shown increased 8-
OHdG levels among individuals with type 2 diabetes (39-40). It has been suggested that 
8-OHdG may be a predictive biomarker for early detection of lifestyle related health 
conditions, such as type 2 diabetes, at population level (41).  
Nutrition plays a vital role in maintaining the oxidative balance. The direct effect 
of nutrition is via providing dietary antioxidants to the exogenous antioxidant network. In 
addition, nutrition affects the oxidative balance indirectly by providing energy to the 
endogenous enzymatic antioxidant system and therefore enhances its function (34). On 
the other hand, over-nutrition and physical inactivity are stressors that contribute to ROS 
production by inducing hyperglycemia and increased glucose accumulation in the muscle 
tissue, adipose tissue and pancreatic cells (33). ROS formed by autoxidation of glucose in 
the muscle tissue, adipose tissue, and pancreatic cells may non-enzymatically react with 
proteins and result in further production of ROS (42).  These pathogenic effects can lead 
to development of insulin resistance, Beta cell dysfunction and glucose intolerance and 
thus result in type 2 diabetogenesis. In animal models ROS impaired insulin synthesis via 
suppression of insulin gene expression in pancreatic Beta cells (37). Antioxidant 
treatment in diabetic rats resulted in improved insulin secretion (37). It has been 
suggested that improvement in oxidative stress may have beneficial effects on the health 
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of individuals with type 2 diabetes (33), and that antioxidant therapy may be a potential 
solution to reduce type 2 diabetes-related complications (37).  
Oxidative stress and vitamin D 
The antioxidant properties of vitamin D3 in human under diabetes conditions are 
not clear. One potential anti-oxidative action of vitamin D may be via suppression of 
intracellular NF-κB which result in down-regulation of pro-inflammatory cytokines (43). 
Diminished pro-inflammatory cytokine levels prevent B cell apoptosis and improves B 
cell survival (36). In addition 1,25(OH)2D3, known as the active form of vitamin D3, 
activates the expression of anti-inflammatory cytokines such as IL-4, IL-10 and TGF-B1 
(44). Deluca et al. (44) suggested that vitamin D may have an immunosuppressive 
properties due to its effect on regulation of pro-inflammatory and anti-inflammatory 
cytokines. Vitamin D supplementation could decrease oxidative stress in human 
colorectal mucosa as measured by 8-OHdG (35). Furthermore, 1,25(OH)2D3 is proved to 
have protective properties against UV-induced oxidative DNA damage in skin cells (46). 
Sun exposure have been shown to be a critical factor in maintaining serum 
vitamin D level in human (47). It has been reported that exposed skin areas` color, such 
as forearm skin color, are significantly associated with serum 25(OH)D3 and that forearm 
skin color may be an accurate predictor of serum vitamin D (47). Several studies showed 
that lighter skin color is associated with higher serum 25(OH)D3 levels (47-50). 
Considering the antioxidant properties of vitamin D and the role of sun exposure in 
maintaining the serum vitamin D level, further investigations are required to assess the 
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association between skin color and oxidative stress under hypovitaminosis D and diabetes 
conditions.  
Type 2 diabetes and early glycation products 
Persistent hyperglycemia leads to non-enzymatic glycation of proteins, known as 
Maillard reaction. In this reversible process the carbonyl group of reducing sugars, such 
as glucose, binds to the amino group on lysine residues of proteins, such as hemoglobin, 
and form early glycation products known as Schiff-bases and Amadori adducts (51). 
Early glycation leads to formation of intermediate glycation products (IGPs) such as 
glycated hemoglobin (HbA1c) and glycated albumin (GA). Continuous elevation in IGP 
level can lead to their irreversible rearrangement to stable advanced glycation end 
products (AGEs) (51-52). AGEs accumulation is a measure of carbonyl, metabolic and 
oxidative stress and serve as a long term metabolic memory, rather than short term 
glycemic control. In contrast, IGPs are better indicators of glycemic control (52). 
Amadori adducts, the major form of IGPs, have 2-3 times higher concentrations of 
glycated products than AGEs (53). HbA1c is currently an established gold standard 
Amadori adduct, reflecting the glycemic control over the period of 8-12 weeks. In 
addition HbA1c is associated with the risk of chronic diabetes related complications such 
as neuropathy, nephropathy, retinopathy and coronary artery disease (53-54). HbA1c 
level, however, can be affected by several factors such as red blood cells turnover, 
uremia, erythropoietin treatment, blood transfusion, anemia, renal malfunction, and iron-
deficiency (53). Based on the twin studies by Sneider et al. (55), HbA1c is strongly 
inherited and influenced by genetics. Furthermore HbA1c reflects on the glycemic 
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control inside the RBCs while serum protein glycation reflects glycemic control in the 
extracellular space (56). 
Albumin is the most abundant protein in plasma and makes more than 50% of 
plasma proteins (57). With a half-life of 14-21 days, albumin is known as the main 
extracellular antioxidant and plays a fundamental role in maintaining the oxidative 
balance (58). Furthermore, albumin has anti-inflammatory and anti-thrombotic properties 
and plays a crucial role in transportation of nutrients, metabolites, hormones and drugs 
while maintaining the osmotic pressure (53).  As a protein with 59 lysine residues, 
albumin is widely involved in extracellular Maillard reactions under hyperglycemic 
conditions (53). Non-enzymatic glycation of albumin happens 10 times faster and 9 times 
more than non-enzymatic glycation of hemoglobin in-vivo (59). It is suggested that 
glycated albumin (GA) may be a more accurate indicator of short term glycemic control 
among individuals with type 1 and type 2 diabetes (60). GA has been linked to diabetes 
induced complications including nephropathy, neuropathy and arteriosclerosis (57). 
Although as compared to hemoglobin, serum albumin is less affected by RBC turnover, 
erythropoietin treatment, blood transfusion, anemia, and iron-deficiency; albumin 
turnover, hepatic cirrhosis and renal malfunction can enhance serum albumin level. It is 
suggested GA/HbA1c ratio may be a better index of glycemic control among individuals 
with diabetes (60).  
Fructosamine is the measure of a combination of circulating glycated proteins, 
such as glyco-lipoproteins and glyco-globlulins (61-62). Knowing albumin is the most 
abundant protein in serum, fructosamine is predominately reflecting GA, however, GA% 
may provide a more accurate and efficient measure of extracellular glycation status over 
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2-3 weeks (62). Furthermore, in case of abnormal albumin levels, fructosamine values 
must be adjusted to albumin levels (62).   
Oxidative stress, inflammation and glycated albumin 
Albumin structure and antioxidant function is greatly suppressed by the Maillard 
reaction. Amadori GA is in fact a stimulant for oxidative stress by producing oxygen free 
radicals and lipid peroxides. Non-enzymatic glycation of albumin also suppresses its 
nutrient/metabolite/drug binding affinity and diminishes its transportation ability (58). In 
macrophage RAW cells (a commercial murine cell-line), GA induced oxidative stress 
activated extracellular signal-regulated kinase (ERK), influenced TGF-β1 production and 
activated NF-κB which plays a critical regulatory role in immunity and inflammatory 
responses (63). In diabetic human endothelial cells, GA increased oxidative stress and 
ROS production by up-regulating NADPH oxidase (64).  This may help to understand the 
role of Amadori-adducts in pathogenesis of diabetes-induced vascular complications. 
Exposure of diabetic mice adipocytes to GA resulted in increased oxidative stress, 
accumulation of ROS in these cells and oxidation of proteins inside them (65). GA-
derived glycation end products (AGEs) may lead to adipocytes dysfunction and insulin 
resistance in adipose tissue. 
Type 2 diabetes and vitamin D 
It has been shown that both, vitamin D deficiency and type 2 diabetes, have 
several risk factors in common: aging, being overweight, having a sedentary lifestyle, and 
being African-American or Hispanic (66). In addition, seasonal variations have been 
observed for both serum vitamin D [25(OH)D3] levels and insulin concentrations 
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suggesting a potential relationship between serum 25(OH)D3 and development of type 2 
diabetes (67-69). Vitamin D directly affects insulin sensitivity, Beta cell function, insulin 
secretion and hence mediates glucose homeostasis (66). Several studies reported an 
association between lower serum vitamin D levels and increased risk of developing type 
2 diabetes (70-72). In addition, a high prevalence of hypovitaminosis D has been 
observed among individuals diagnosed with type 2 diabetes, compared to individuals 
without type 2 diabetes (73). Beside its effect on Beta cell function and insulin 
sensitivity, vitamin D also regulates calcium homeostasis which plays an important role 
in regulating insulin secretion (74). 
An extensive review with a meta-analyses, proposed that the direct role of vitamin 
D on glucose homeostasis is mediated via binding of its metabolically active form, 
1,25(OH)2D3, to the vitamin D receptors (VDR) in pancreatic Β-cells, activation of 
25(OH)D3 to 1,25(OH)2D3 by the enzyme 1-α-hydroxylase (expressed in B-cells) within 
B-cells, stimulating the insulin receptor gene transcription, enhancing the expression of 
insulin receptor and hence affecting the insulin-mediated glucose transport (68). VDRs 
also exist in skeletal muscle and adipose tissues which are insulin targets and are 
responsible for peripheral insulin sensitivity. VDR expression in human skeletal muscle 
tissue, which declines with age, stimulates regulation of protein synthesis and results in 
diminished insulin sensitivity among older adults (75). In addition, animal studies 
showed impaired insulin secretion in mice with inactive VDRs (76). 
The indirect role of vitamin D in glucose homeostasis is determined by its effect 
on regulation of extracellular calcium and calcium flux in the pancreatic B-cells (68). 
Imbalance between the extracellular and intracellular calcium pools influences the ability 
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of B-cells to release insulin. Serum vitamin D concentration is inversely associated with 
Parathyroid hormone (PTH) level, which regulates intracellular calcium (77). In animal 
and in-vitro study, hypovitaminosis D was found to cause augmented PTH levels, which 
resulted in elevated intracellular calcium levels (78). In adipose tissue (an insulin target 
tissue), sustained augmentation in cytosolic calcium level was associated with increased 
insulin resistance (78). The insulin mediated glucose uptake was decreased by 30% 
among PTH injected rats (68). This could be due to increased phosphorylation of GLUT-
4 (an insulin-regulated glucose transporter in adipose and muscle tissue) in the presence 
of elevated cytosolic calcium levels. Cross-sectional studies reported an inverse relation 
between serum vitamin D level and insulin sensitivity (79-81). In addition, vitamin D and 
calcium supplementation attenuated insulin resistance among non-diabetic older adults 
with impaired fasting plasma glucose (FPG) (82). 
Vitamin D and glycated albumin  
The relationship between vitamin D and GA is yet to be studied. Furthermore, to 
our knowledge no studies have yet investigated the effectiveness of vitamin D3 
supplementation on GA, as a biomarker of short-term glycemic control, among 
individuals with or without diabetes. Despite lack of evidence on the relationship 
between GA and vitamin D, HbA1c have been negatively linked to serum 25(OH)D level 
(83-85). Clinical trials on vitamin D supplementation and its impact on glycemic 
improvement (specifically on HbA1c) among individuals with type 2 diabetes, however, 
could not consistently support the effectiveness of vitamin D supplementation on 
glycemic control (86). It is not clear whether improvement in serum vitamin D may 
improve Amadori formation of GA. We assume vitamin D may improve GA level via its 
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antioxidant properties. Furthermore, since vitamin D has a high binding affinity for 
adipose tissue, it may prevent the GA-induced oxidative stress in adipocytes via its 
antioxidant capabilities. Albumin is a transporter of vitamin D; therefore, binding of 
vitamin D to serum albumin may affect its affinity to glucose under non-enzymatic 
conditions. In that case, vitamin D may be effective in prevention of GA-derived AGEs 
production. 
Significance of the study 
Effectiveness of vitamin D3 supplementation on DNA/RNA oxidative stress 
under type 2 diabetes condition in human is not clear. Trials among human subjects are 
needed to investigate and quantify the potential beneficial impact of vitamin D3 
supplementation at different dosages among individuals with vitamin D deficiency. 
Therefore the aim of this study was to investigate the effect of 4000 IU and 6000 IU daily 
supplementation of vitamin D3 for 3 and 6 months on biomarkers of DNA/RNA 
oxidative stress, 8-OHdG, in individuals with type 2 diabetes and serum vitamin D 
[25(OH)D3] insufficiency or deficiency. In addition, we investigated the relationship 
between skin exposure score, as a measure of sun exposure, and oxidative stress in 
individuals with type 2 diabetes and 25(OH)D3 deficiency or insufficiency. We 
hypothesized that daily supplementation with 4000 and 6000 IU of vitamin D3 for 6 
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and 
vitamin D insufficiency or deficiency, compared to baseline. To our knowledge, this is 
the first study investigating the effects of vitamin D3 supplementation on 8-OHdG among 
human subjects with type 2 diabetes. Furthermore, we hypothesized individuals with 
lighter forearm skin color will have lower 8-OHdG levels compared to those with darker 
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forearm skin color, at baseline and that individuals with higher skin exposure scores, as 
measured by the difference between exposed and unexposed skin colors, will have lower 
8-OHdG levels.  
To our knowledge, there is currently no studies that assessed the possible effects 
of vitamin D3 supplementation on serum GA levels among individuals with or without 
type 2 diabetes. While GA is a relatively new biomarker for type 2 diabetes management, 
almost all the current studies on vitamin D supplementation in type 2 diabetes have been 
targeting fasting plasma glucose and HbA1c as the markers of glycemic control. The 
findings of this study will help to fill the gap on the possible beneficial effects of vitamin 
D3 on GA, as the most abundant Amadori-protein in human serum. Therefore, the aim of 
this study was to investigate the effectiveness of daily supplementation with 4000 IU and 
6000 IU vitamin D3 for 3 months and 6 months on GA. 
Furthermore, this study was aimed to assess the relationship between DII and 
biomarker of inflammation (CRP), oxidative stress (8-OHdG), glycemic status [glycated 
hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level among individuals 
with type 2 diabetes and vitamin D deficiency/insufficiency. To our knowledge this is the 
first study assessing the relationship between DII, 8-OHdG, HbA1c, GA and insulin 
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. 
Specific aims and hypothesis 
Specific aim 1: 
To investigate the association between dietary inflammatory biomarker (DII) and 
biomarker of inflammation (CRP), oxidative stress (8-OHdG), glycemic status [glycated 
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hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level among individuals 
with type 2 diabetes and vitamin D deficiency/insufficiency.  
Hypothesis: DII is positively associated with serum CRP, 8-OHdG, GA%, HbA1c 
and inversely associated with insulin level. 
Specific aim 2: 
To investigate the effect of 4000 and 6000 IU/day of vitamin D3 supplementation 
for 6 months on biomarker of oxidative stress (8-hydroxy-2`-deoxyguanosine) in 
individuals with type 2 diabetes and serum vitamin D insufficiency/deficiency. 
Hypothesis: Daily supplementation with 4000 and 6000 IU of vitamin D3 for 6 
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and 
vitamin D insufficiency/deficiency, compared to baseline. 
Specific aim 3: 
To investigate the effect of 4000 and 6000 IU/day of vitamin D3 supplementation 
for 6 months on biomarker of glycemic status [glycated albumin (GA%)] in individuals 
with type 2 diabetes and serum vitamin D insufficiency/deficiency. 
Hypothesis: Daily supplementation with 4000 and 6000 IU of vitamin D3 for 6 
months will decrease serum GA% in individuals with type 2 diabetes and vitamin D 
insufficiency/deficiency, compared to baseline. 
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CHAPTER II: ASSOCIATION BETWEEN DIETARY INFLAMMATORY 
INDEX AND SERUM VITAMIN D, OXIDATIVE STRESS, INFLAMMATION, 
AND GLYCEMIC STATUS IN ADULTS WITH TYPE 2 DIABETES 
Introduction 
Diabetes mellitus is ranked as the seventh leading cause of death in the United 
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for 
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S 
population) were diagnosed with diabetes while more than 8 million cases were 
undiagnosed (2). As estimated by the American Diabetes Association in 2013, total direct 
and indirect costs of diabetes in the U.S. were $245 billion in 2012. Individuals with 
diabetes had 2.3 times more medical expenditures compared to individuals without 
diabetes (3). Native Americans had the highest rates of diagnosed diabetes (15.9%) 
among all race/ethnic groups aged 20 years and older, followed by African Americans 
(13.2%) and Hispanics (12.8%) (3). Type 2 diabetes accounts for 90-95% of all 
diagnosed diabetes cases among adults. Insulin resistance and pancreatic Beta cell 
dysfunction are the major pathophysiological abnormalities that lead to type 2 diabetes 
pathogenesis and progression (4). 
Insulin is a peptide hormone that unlocks the cells to absorb glucose from the 
bloodstream and inhibits gluconeogenesis by the liver. Pancreatic Beta cells are 
responsible for insulin production and secretion. Both decline in insulin sensitivity 
(insulin resistance) and insufficient insulin production result in accumulation of excess 
 
25 
glucose in blood stream and starvation of the cells for glucose, which can lead to several 
organ or system damages. 
Insulin resistance and hyperglycemia are linked to systemic inflammation (5). 
Inflammation is a defense mechanism of the innate immunity. As evidenced by a 9-year 
case-cohort study of 10,275 adults, systemic inflammation precedes diabetes and low-
grade inflammation plays a critical intermediary role in diabetogenesis (6). Accumulating 
evidence suggest that type 2 diabetes is a condition of innate immune system, and it may 
be the result of long-term activation of an acute phase cytokine-mediated response of the 
innate immune system (7). Although this acute-phase reaction of the innate immune 
system is initially stimulated to maintain homeostasis in response to environmental 
stressors, it is suggested that the sustained activation of this mechanism may lead to 
pathogenesis of many chronic inflammatory conditions, including type 2 diabetes (7). In 
this process, stressors such as age, over-nutrition, physical inactivity, visceral adiposity 
and oxygen metabolites stimulate the innate immune system comprised of adipose tissue 
macrophages and monocytes to produce and release pro-inflammatory cytokines such as 
interleukin (IL)-1, IL-6, IL-18 and tumor necrosis factor-alpha (TNF-α) (8). Elevated 
levels of pro-inflammatory cytokines elicit the liver to synthesize the acute phase 
proteins, such as C-reactive protein (CRP), while inducing dyslipidemia [increased low 
density lipoproteins (LDL) and decreased high density lipoproteins (HDL)] by 
hepatocytes (8). In addition, it is suggested that augmented cytokine levels elicit β-cell 
apoptosis and result in β-cell dysfunction (9). Furthermore, pro-inflammatory cytokines 
stimulate the brain to release adrenocorticotropic hormone, which results in increased 
cortisol level (8). Cortisol is a glucocorticoid that is a functional antagonist of insulin. 
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While insulin diminishes hepatic gluconeogenesis, cortisol promotes gluconeogenesis 
and impedes the glucose uptake by insulin (10). Cortisol directly suppresses the insulin 
release by the pancreatic β cells (10). Increased cortisol is linked to insulin resistance, 
glucose intolerance and central obesity (11). 
Systemic inflammation has been linked to oxidative stress (12). Increased 
Reactive Oxygen Species (ROS) production and impaired oxidative balance result in 
activation of nuclear factor κB (NF-κB), which plays a critical regulatory role in 
immunity and inflammatory responses (13). NF-κB regulates the expression of a variety 
of genes such as growth factors and pro-inflammatory cytokines such as IL-1β and TNF-
α. NF-κB enhances a signaling cascade which leads to sustained production of ROS and 
causes low grade inflammation (14). As mentioned earlier, continued production of pro-
inflammatory cytokines results in an acute phase response by the innate immunity and 
lead to β cell apoptosis and dysfunction. This process diminishes the ability of the 
pancreas to produce and release insulin and thus contributes to type 2 diabetogenesis. 
Nutrition plays a critical role in systemic inflammation regulation (15). It has 
been shown that dietary patterns affect pro-inflammatory and anti-inflammatory 
cytokines’ balance and therefore enhance the risk of developing inflammatory diseases 
(16). A comprehensive review of observational and prospective studies, along with 
randomized controlled trials, suggested an anti-inflammatory property for the 
Mediterranean dietary pattern (higher consumption of fruits and vegetables, unrefined 
carbohydrates, and fish, moderate consumption of dairy products and wine, and low 
consumption of non-fish meat (17), compared to the Western diet (higher consumption of 
refined carbohydrates, saturated fat, and red meat) (18). Consumption of antioxidant 
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vitamins, such as vitamin C, E, and β-Carotene, and polyunsaturated fatty acids (PUFA), 
such as Omega-3 fatty acids, have been linked to lower systemic inflammation (19), 
while higher intakes of total and saturated fat have been associated with higher systemic 
inflammation (20-21). 
The Dietary Inflammatory Index (DII) is a comprehensive literature-derived tool 
that was first developed by Caviccia et al. (22) in 2009 to assess the inflammatory 
potential of each individual's diet. Out of 2700 screened articles published from 1950 to 
2007, 929 were considered for the development of the algorithm to formulate DII. The 
objective of this project was to develop a methodology which could score dietary intakes 
on a spectrum of maximally anti-inflammatory to maximally pro-inflammatory (22). 
Caviccia at al. validated the DII scores against CRP. The results of the validation study 
showed a significant relationship between DII, as a categorical variable, and CRP (22). 
Later in 2013, DII was updated by Shivappa et al. (23). The updated DII, is based on 
1943 articles out of 6500 screened, published in 2010-2013 in regards to the effect of diet 
on 6 inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP). The updated 
DII includes forty-five pro-inflammatory and anti-inflammatory food parameters, 
compared to forty-two in the initial DII. The food parameters include: alcohol, vitamin 
B12, vitamin B6, β-Carotene, caffeine, carbohydrate, cholesterol, energy, eugenol, total 
fat, fiber, folic acid, garlic, ginger, iron, magnesium, monounsaturated fatty acids 
(MUFA), niacin, n-3 fatty acids, n-6 fatty acids, onion, protein, PUFA,  riboflavin, 
saffron, saturated fat, selenium, thiamin, trans fat, turmeric, vitamin A, vitamin C, 
vitamin D, vitamin E, zinc, green/black tea, flavan-3-ol, flavones, flavonols, flavonones, 
anthocyanidins, isoflavones, pepper, thyme/oregano, rosemary. After fitting the DII to 
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eleven dietary intake data sets from across the world, the globally adjusted scores ranged 
from +7.98 (maximally pro-inflammatory) to -8.87 (maximally anti-inflammatory). High 
DII values (pro-inflammatory diet) have been linked to low grade inflammation and 
insulin resistance (24), metabolic syndrome (25), cardiovascular diseases (26), colorectal 
cancer (27-28), pancreatic cancer (29), gastric cancer (30), and ovarian cancer (31). 
The aim of this study was to assess the relationship between DII and biomarker of 
inflammation (CRP), oxidative stress [8-hydroxydeoxyguanosine (8-OHdG)], glycemic 
status [glycated hemoglobin (HbA1c) and glycated albumin (GA)] and insulin level 
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. To our 
knowledge this is the first study assessing the relationship between DII, 8-OHdG, 
HbA1c, GA and insulin among individuals with type 2 diabetes and vitamin D 
deficiency/insufficiency. 
Materials and methods: 
This is an ancillary study of data from the parent study by Huffman et al. (32) that 
investigated the effects of vitamin D3 supplementation on cardiovascular disease 
biomarkers. The outcome of this study is explained in detail elsewhere (32). 
The study design is described below: 
Study participants were recruited from 2 sources: 1) Community areas by 
distributing flyers that included the purpose of the study, inclusion and exclusion criteria, 
and the investigators information. 2) The Borinquen Health Care Center and the Clinical 
Care Medical Center.  Weekly visits were conducted to recruit study participants. 
Interested individuals called the investigators and expressed their willingness to 
 
29 
participate in the study, and were asked to answer a few eligibility pre-screening 
questions. Qualified individuals were invited for screening at the Human Nutrition 
Laboratory, Florida International University. After signing the informed consent form, 
fasting blood samples were collected, and screening questionnaires were administered to 
evaluate whether the inclusion criteria were met (33). 
The inclusion criteria were being 30-70 years old, being African-American or 
Hispanic, having Type 2 diabetes, and being vitamin D insufficient [25(OH)D3 < 30 
ng/mL]. Exclusion criteria were being pregnant or lactating, taking vitamin D 
supplements, injecting insulin, suffering from thyroid, hepatic and/or renal complications, 
and suffering from HIV and cancer. Participants of the current study were contacted at 
two-time points: 
Screening: During screening the eligibility of the participants to enroll in the 
study was assessed based on the inclusion and exclusion criteria. Participants signed an 
informed consent form before the start of data collection. Fasting blood was collected for 
screening of vitamin D status. 
Baseline: All participants who met the inclusion criteria participated in the study. 
Blood collection, anthropometric measurements, Willett food frequency questionnaire 
and a socio-demographic questionnaire were administered at baseline. 
Measurements of variables: 
a. Socio-demographic questionnaire 
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A socio-demographic questionnaire was used to collect information about age, 
gender, race/ethnicity, years living in the United States and years having type 2 diabetes. 
b. Anthropometric measurements 
Height and weight measurements were taken by using a SECA balance scale 
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist 
circumference was measured by using a measuring tape to the nearest 0.1 cm. Systolic 
and diastolic blood pressure were measured in a sitting position by using an automated 
arm-cuff monitor. All measurements were done twice and the average of two readings 
was included in the analysis. 
c. Dietary intake 
A food frequency questionnaire (FFQ) developed by Willett et al. (34) was used 
to assess dietary intake for each individual. This questionnaire was validated previously 
among individuals from different racial and ethnic backgrounds (34-37). In a study 
among Cuban-Americans, Nath et al. (35) validated Willet FFQ against a 3-day food 
record and reported no significant differences in the nutrient intakes estimated by these 
two methods. Ethnic food items were added to the questionnaire. This study suggested 
Willet FFQ may be a reasonable tool for estimating macronutrients and alcohol among 
Cuban-Americans (35). In the present study participants self-reported their average 
consumption of 131 food items for the past 12 months. Frequency of intake for each food 
item was ranged from ‘‘never’’ to ‘‘6 times or more daily’’. Consumption of 
multivitamin and mineral supplements were also recorded. In order to calculate each 
individuals’ macronutrient and micronutrient intake, the frequency of consumption of 
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each food item was multiplied by its nutrient value (Harvard University Food 
Consumption Data Base, Channing Laboratory, Boston, MA). 
d. Calculation of the dietary inflammatory index (DII) score 
DII for each individual was calculated based on the values obtained from the 
Willett FFQ. In this process, thirty-four foods and constituents parameters were included 
in the analysis (Table 1). To obtain a ‘z score’ relative to standard global mean, estimated 
intake of each food parameter for each individual was subtracted from the global standard 
mean and then divided by the global standard deviation. To prevent possible right 
skewing, calculated z-scores were converted to a percentile score centered on 0; First a 
percentile ranking was calculated for each z score and then each value was multiplied by 
2 and subtracted by 1 to obtain values range between -1 and +1. The calculated centered 
score for each food item was then multiplied by the respective food parameter’s specified 
inflammatory effect score (23). All the obtained food parameter scores for each 
participant were summed up to create the overall DII score for each individual. More 
positive scores reflect more pro-inflammatory dietary intakes. 
e. Blood collection and analysis 
Fasting venous blood was collected by a certified phlebotomist (15 mL).  After 
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were 
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose 
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c 
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics 
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic 
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ). Oxidative stress 
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biomarker, 8-hydroxydeoxyguanosine (8-OHdG), was assessed using a human 
DNA/RNA oxidative damage competitive enzyme-linked immunosorbent assay (Cayman 
Chemical, Ann Arbor, MI, item No 589320). 
Statistical analysis: 
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago, 
IL, USA) was used for performing the statistical analysis. P-value ≤0.05 was considered 
significant (two-tailed). DII score was categorized into quartiles: Q1 (-5.214, -1.827), Q2 
(-1.826, -0.653), Q3 (-0.652, +1.138), Q4 (+1.138, +3.999). Descriptive statistics were 
conducted for baseline characteristics; for continuous variables means and standard errors 
(SE) and for categorical variables frequencies/percentages were determined. Pearson 
correlation analysis was used to assess the correlation between variables within each 
quartile. Linear regression analysis was used to test the association between DII versus 
CRP, DII versus 8-OHdG, and DII versus GA% within each quartile. The multivariable 
model was later adjusted for confounders. 
Results: 
Out of 92 individuals who were screened at baseline, 77 met the inclusion criteria 
and participated in the interventions. Nine subjects were excluded due to missing values 
for 8-OHdG and GA%. Sixty-eight participants, 41 females and 27 males, were included 
in the current analysis. Baseline characteristics of participants for the entire sample and 
for each quartile [Q1 (-5.214, -1.827), Q2 (-1.826, -0.653), Q3 (-0.652, +1.138), Q4 
(+1.138, +3.999)] are shown in table 2. There were 17 participants in each quartile. Mean 
age was 54.94 ± 7.93 with 60.3 % of participants being female. Participants in the first 
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quartile of DII (the least pro-inflammatory diet) were more likely to be women and had 
the highest systolic blood pressure (SBP). Participants in the third percentile of DII were 
more likely to be female, had higher BMI scores and higher CRP, HbA1c and fasting 
plasma glucose (FPG) levels. Participants in the fourth percentile of DII (more pro-
inflammatory diet) were less likely to be female, had higher 8-OHdG, GA%, HbA1c, 
FPG and parathyroid hormone (PTH). 
Pearson correlation analysis showed a statistically significant correlation between 
DII Q1 and BMI (r=0.520, p=0.033), and PTH (r=0.510, p=0.037). For DII Q2, there 
was a significant correlation between DII score and HbA1c (r=0.529, p=0.029). For DII 
Q3, there was a significant correlation between DII score and insulin level (r=0.620, 
p=0.008). For DII Q4, there was a significant correlation between DII score and SBP 
(r=0.532, p=0.0.028). Linear regression models assessing the association between 
quartile DII scores and BMI, PTH, HbA1c, insulin, and SBP were conducted (table 3). 
The unadjusted model showed no significant associations between DII, HbA1c and PTH 
(Q1-Q4).  There was a marginally significant association between DII Q1 and BMI 
(p=0.057). A significant inverse association was observed between DII Q3-Q4 and 
insulin level (p=0.006 and p=0.030, respectively). After adjusting for covariates, age, 
gender, waist circumference, FPG and 25(OH)D, the model remained significant for both 
Q3 and Q4 (p=0.040 and p=0.049, respectively). There was a significant association 
between SBP and DII in Q4 (p=0.029). However, after adjusting the model for the 
covariates the model lost significance. 
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Discussion: 
To our knowledge, this is the first study examining the associations between 
dietary inflammatory index (DII) and biomarkers of inflammation (CRP), oxidative stress 
(8-OHdG), and glycemic status [glycated hemoglobin (HbA1c) and glycated albumin 
(GA%)] among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. 
The results of this cross-sectional analysis of data showed no statistically significant 
relationship between DII, CRP, 8-OHdG, HbA1c and GA%. This confirms the findings 
of Almeida et al. (38) who found no significant associations between DII score and CRP 
level among adolescents from the LabMed physical activity study. Furthermore, in a 
study among 2,567 postmenopausal women, Tabung et al. (39) found no significant 
association between DII and CRP. However, Tabung et al. found another biomarker of 
inflammation, IL-6, to be significantly associated with DII. This is not consistent with the 
results of Cavicchia et al. (22) and Shivappa et al. (23) who found DII to be a significant 
predictor of CRP. It may be due to the smaller sample size in the present study (n=68 
compared to n=600 in the Cavicchia et al.). Furthermore, DII is a literature-derived tool 
based on 1,943 articles on the effect of diet on a panel of inflammatory biomarkers (IL-
1β, IL-4, IL-6, IL-10, TNF-α, and CRP). It is not clear whether any of these biomarkers 
of inflammation are more sensitive to DII score across various racial/ethnic groups. In 
addition, the dietary intakes have been recorded with different methods across the studies. 
For the example Cavicchia at al. (22) obtained the dietary intakes data for each 
participant from a randomly selected 24-hour recall. This is while Almeida et al. (38) 
used a semi-quantitative food frequency questionnaire validated for the Portuguese 
population. It is worth noting that not all the studies used all forty-five food parameters 
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included in the updated DII developed by Shivappa et al. (23). This may be due to 
unavailability of some dietary information caused by the various methods of dietary data 
collection. In our study, we included 34 food parameters, based on the availability of the 
dietary information. Food items such as eugenol, garlic, ginger, onion, saffron, turmeric, 
green/black tea, Isoflavones, pepper, thyme/oregano, and rosemary were not available 
and were not included in the present study.  This may be a source of variation in DII 
range in across different studies; The DII range in our study was (-5.214, +3.999), while 
the range for the global database developed by Shivappa et al. (23) was (-8.87, +7.98). 
A significant correlation was found between DII score and HbA1c (r=0.529, 
p=0.029) in the second quartile (Q2) in the present study, and the unadjusted linear 
model also showed an association between DII and HbA1c. These results were 
inconsistent with findings of Wouderndergh et al. (40) who did not find an association 
between adopted DII and HbA1c among 1,024 Dutch participants. The present study 
found a significant inverse association between DII Q3-Q4 and insulin levels (p=0.006 
and p=0.030, respectively). After adjusting for covariates, age, gender, waist 
circumference, FPG and 25(OH)D, the model remained significant (p=0.040 and 
p=0.037). This suggests individuals with higher pro-inflammatory dietary intakes may 
have lower insulin levels. This means a pro-inflammatory diet may play a role in insulin 
production and release from β-cells in pancreas. Moslehi et al. (41) reported no 
significant association between DII and insulin levels and insulin resistance among 2,975 
Iranian adults. This may be due to the health status difference among the participants of 
this study (without type 2 diabetes), compared to the present study included only 
individuals with type 2 diabetes. In addition, mean age was lower (45 ± 11.7 years) in the 
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study conducted by Moslehi et al. (41), compared to the present study (54.94 ± 7.93 
years). 
There was a significant association between SBP and DII in Q4 (p=0.029). This 
may suggest more pro-inflammatory dietary patterns can lead to a higher risk of 
developing blood pressure abnormalities. However, after adjusting the model for the 
covariates mentioned above, the model lost significance. Consistent with our findings, 
Vissers et al (42) also found pro-inflammatory diets associated with increased risk of 
developing hypertension among a cohort of middle-aged Australian woman. 
Conclusion: 
A pro-inflammatory diet may be associated with increased risk of hypo-
insulinemia and incidence of higher SBP among individuals with type 2 diabetes and 
vitamin D deficiency/insufficiency. The limitations of this study were the small sample 
size and the exclusion of individuals with adequate serum 25(OH)D levels to serve as a 
base for comparison. Furthermore, due to unavailability of the dietary information, eleven 
food parameters were not included in the DII calculations. The strengths of the study 
were its innovation in studying the association between DII and biomarkers of 
inflammation (CRP), oxidative stress (8-OHdG), and glycemic status (HbA1c and GA%) 
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. The 
results of this study may serve as a basis for future nutrition interventions to improve 
anti-inflammatory intakes, developing culturally appropriate anti-inflammatory 
counseling and improving the health status of individuals with type 2 diabetes. 
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Table 1. Thirty-five food parameters obtained from the food frequency questionnaire to 
calculate the dietary inflammatory index 
Food parameter Overall inflammatory effect score 
Alcohol (g) -0.278 
Vitamin B12 (µg) 0.106 
Vitamin B6 (mg) -0.365 
β-Caroten (µg) -0.584 
Caffeine (g) -0.110 
Carbohydrate (g) 0.097 
Cholesterol (mg) 0.110 
Energy (kcal) 0.180 
Total fat (g) 0.298 
Fibre (g)  -0.663 
Folic acid (µg) -0.190 
Iron (mg) 0.032 
Magnesium (mg) -0.484 
MUFA (g) -0.009 
Niacin (mg) -0.246 
n-3 fatty acids (g) -0.436 
n-6 fatty acids (g) -0.159 
Protein (g) 0.021 
PUFA (g) -0.337 
Riboflavin (mg) -0.068 
Saturated fat (g) 0.373 
Selenium (µg) -0.191 
Thiamin (mg) -0.098 
Trans fat (g) 0.229 
Vitamin A (RE)* -0.401 
Vitamin C (mg) -0.424 
Vitamin D (µg) -0.446 
Vitamin E (mg) -0.419 
Zinc (mg)  -0.313 
Flavan-3-ol (mg) -0.415 
Flavones (mg) -0.616 
Flavonols (mg) -0.467 
Flavonones (mg) -0.250 
Anthocyanidins (mg) -0.131 
Eugenol, garlic, ginger, onion, saffron, turmeric, green/black tea, Isoflavones, pepper, 
thyme/oregano, and rosemary were not included in the present study. *RE = retinol 
equivalent. 
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Table 2. Baseline Characteristics 
Characteristics Total 
(N= 68) 
Mean ± SE 
Q1* 
(n=17) 
Mean ± SE 
Q2* 
(n=17) 
Mean ± SE 
Q3* 
(n=17) 
Mean ± SE 
Q4* 
(n=17) 
Mean ± SE 
Age (years)  54.94 ± 7.93 54.47 ± 6.57 56 ± 9.93 54.06 ± 6.47 55.24 ± 8.81 
Gender (% 
female) 
60.3 58.8 58.8 76.5 47.1 
BMI (kg/m²) 33.70 ± 6.59 32.65 ± 4.08 32.86 ± 5.91 37.14 ± 8.72 32.15 ± 6.10 
SBP 133.706 ± 
22.59 
136.56 ± 
21.25 
135.59 ± 
18.92 
130.65 ± 
25.62 
132.03 ± 
25.18 
DBP 84.97 ± 12.57 85.47 ± 9.26 85.29 ± 10.63 85.94 ± 17.02 83.18 ± 
12.99 
25(OH)D 
(ng/mL) 
22.34 ± 6.68 22.78 ± 6.34 22.40 ± 5.93 21.79 ± 6.41 22.38 ± 8.31 
CRP 7.91 ± 10.60 7.87 ± 10.87 7.92 ± 12.56 10.43 ± 12.50 5.43 ± 5.01 
8-OHdG 
(pg/mL) 
8068.94 ± 
2158.13 
7787.73 ± 
2010.92 
8174.39 ± 
3018.67 
7572.12 ± 
1835.72 
8741.50 ± 
1462.46 
GA% 5.51 ± 3.28 5.29 ± 2.84 6.03 ± 4.30 4.49 ± 1.80 6.24 ± 3.65 
HbA1c 8.35 ± 2.28 8.14 ± 2.01 7.87 ± 1.95 9.13 ± 2.62 8.26 ± 2.47 
FPG (mg/dL) 184.26 ± 
79.02 
183.82 ± 
71.65 
173.65 ± 
70.92 
203.12 ± 
99.19 
176.47 ± 
74.73 
Insulin 
(mIU/L) 
12.64 ± 11.38 11.58 ± 8.71 17.46 ± 17.05 11.46 ± 6.68 10.08 ± 4.95 
PTH (pg/mL) 39.52 ± 
18.139 
33.90 ± 16.40 34.52 ± 17.76 42.87 ± 18.19 46.49 ± 
17.47 
*Quartiles; Q1 (-5.214, -1.827), Q2 (-1.826, -0.653), Q3 (-0.652, +1.138), Q4 (+1.138, +3.999). 
BMI = Body mass index. SBP = systolic blood pressure. DBP = diastolic blood pressure. CRP = 
C-reactive protein. GA% = Glycated albumin/albumin *100. FPG = fasting plasma glucose, PTH 
= parathyroid hormone. 
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Table 3. Association between Dietary Inflammatory Index and covariates within each 
quartile 
Parameter*           Unadjusted                                                    Adjusted 
    β         SE         T       P-value                β         SE        T        P-value 
Insulin (mIU/L) 
            Q1 
            Q2 
            Q3 
            Q4 
 
0.340     1.418    1.398    0.182 
0.088     2.104    0.342    0.737 
0.636     0.703    3.188    0.006†              -0.594   0.921  -2.362    0.040† 
-0.526    0.505   -2.398   0.030†              -0.619   0.635  -2.246    0.049† 
SBP (mmHg)    
            Q1 
            Q2 
            Q3 
            Q4 
 
0.447     3.29     1.937     0.072 
0.100     2.09     0.388     0.703 
-0.400    3.32    -1.692    0.111 
0.528     2.57     2.408     0.029†                0.486    0.23    1.815     0.10 
*Other covariates in the multiple regression model were age, gender, waist circumference 
and fasting plasma glucose and 25(OH)D. † Statistically significant. P < 0.05 is 
considered significant. 
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CHAPTER III: EFFECT OF VITAMIN D3 SUPPLEMENTATION ON 
DNA/RNA OXIDATIVE STRESS IN ADULTS WITH TYPE 2 DIABETES   
Introduction 
Oxidative stress is caused by an imbalance between oxygen metabolites 
production and ability of the endogenous and exogenous antioxidant networks to 
neutralize them (1). Reactive oxygen species (ROS), such as superoxide anion (O2
−), 
hydrogen peroxide (H2O2), hydroxyl radical (OH
°) and peroxynitrite (OONO−), have one 
or more unpaired electrons and are highly reactive (2). ROS may attack other molecules 
to take an electron from them and stabilize (3). They can damage proteins, lipids and 
DNA. These oxidized biomolecules may trigger further oxidizing chain reactions that 
may result in production of new free radicals (3-4). Oxidative stress plays a pivotal role 
in systemic inflammation, type 2 diabetes development and its related complications (5). 
Although ROS production is one of the primary defense mechanisms, increased ROS 
production may result in impaired oxidative balance which leads to activation of nuclear 
factor κB (NF-κB). NF-κB plays a critical regulatory role in immunity and inflammatory 
responses (4). NF-κB regulates the expression of a variety of genes such as growth 
factors and pro-inflammatory cytokines and enhances a signaling cascade which leads to 
sustained production of ROS and causing low grade inflammation (6). Continued 
production of pro-inflammatory cytokines results in an acute phase response by the innate 
immunity and lead to pancreatic β cell apoptosis and dysfunction. This process 
diminishes the ability of the pancreas to produce and release insulin and thus causes type 
2 diabetes.  
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ROS induced oxidation of guanine residues of DNA can damage the DNA strands 
and produce 8-hydroxydeoxyguanosine (8-OHdG) (7). Several studies had shown 
increased 8-OHdG levels among individuals with type 2 diabetes (8-9). It has been 
suggested that 8-OHdG may be a predictive biomarker for early detection of lifestyle 
related health conditions, such as type 2 diabetes, at population level (10).  
Nutrition plays a vital role in maintaining the oxidative balance. The direct effect 
of nutrition is via providing dietary antioxidants to the exogenous antioxidant network. In 
addition, nutrition affects the oxidative balance indirectly by providing energy to the 
endogenous enzymatic antioxidant system and therefore enhances its function (3). On the 
other hand, over-nutrition and physical inactivity are stressors that contribute to ROS 
production by inducing hyperglycemia and increased glucose accumulation in the muscle 
tissue, adipose tissue and pancreatic cells (2). ROS formed by autoxidation of glucose in 
the muscle tissue, adipose tissue, and pancreatic cells may non-enzymatically react with 
proteins and result in further production of ROS (11).  These pathogenic effects can lead 
to development of insulin resistance, Beta cell dysfunction and glucose intolerance and 
thus result in type 2 diabetogenesis. In animal models, ROS impaired insulin synthesis 
via suppression of insulin gene expression in pancreatic Beta cells (6). Antioxidant 
treatment in diabetic rats resulted in improved insulin secretion (6). It has been suggested 
that decreasing oxidative stress may have beneficial effects on the health of individuals 
with type 2 diabetes (2), and that antioxidant therapy may be a potential solution to 
reduce type 2 diabetes-related complications (6).  
The antioxidant properties of vitamin D3 in human under diabetes conditions are 
not clear. One potential anti-oxidative action of vitamin D may be via suppression of 
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intracellular NF-κB which result in down-regulation of pro-inflammatory cytokines (12). 
Diminished pro-inflammatory cytokine levels prevent B cell apoptosis and improves B 
cell survival (5). In addition, 1,25(OH)2D3 known as the active form of vitamin D3, 
activates the expression of anti-inflammatory cytokines such as IL-4, IL-10 and TGF-B1 
(13). Deluca et al. (13) suggested that vitamin D may have an immunosuppressive 
property due to its effect on regulation of pro-inflammatory and anti-inflammatory 
cytokines. Vitamin D supplementation could decrease oxidative stress in human 
colorectal mucosa as measured by 8-OHdG (14). Furthermore, 1,25(OH)2D3 is proved to 
have protective properties against UV-induced oxidative DNA damage in skin cells (15). 
Sun exposure have been shown to be a critical factor in maintaining serum 
vitamin D level in human (16). It has been reported that exposed skin areas’ color, such 
as forearm skin color, are significantly associated with serum 25(OH)D3 and that forearm 
skin color may be an accurate predictor of serum vitamin D (16). Several studies showed 
that lighter skin color is associated with higher serum 25(OH)D3 levels (16-19). 
Considering the antioxidant properties of vitamin D and the role of sun exposure in 
maintaining the serum vitamin D level, further investigations are required to assess the 
association between skin color and oxidative stress under hypovitaminosis D and diabetes 
conditions.  
Effectiveness of vitamin D3 supplementation on DNA/RNA oxidative stress 
under type 2 diabetes condition in human is not clear. Trials among human subjects are 
needed to investigate and quantify the potential beneficial impact of vitamin D3 
supplementation at different dosages among individuals with vitamin D deficiency. 
Therefore, the aim of this study was to investigate the effect of 4000 IU and 6000 IU 
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daily supplementation of vitamin D3 for 3 and 6 months on a biomarker of DNA/RNA 
oxidative stress, 8-OHdG, in individuals with type 2 diabetes and serum vitamin D 
[25(OH)D3] insufficiency or deficiency. In addition, we investigated the relationship 
between skin exposure score, as a measure of sun exposure, and oxidative stress in 
individuals with type 2 diabetes and 25(OH)D3 deficiency or insufficiency. We 
hypothesized that daily supplementation with 4000 and 6000 IU of vitamin D3 for 6 
months will decrease serum 8-OHdG level in individuals with type 2 diabetes and 
vitamin D insufficiency or deficiency, compared to baseline. To our knowledge, this is 
the first study investigating the effects of vitamin D3 supplementation on 8-OHdG among 
human subjects with type 2 diabetes. Furthermore, we hypothesized individuals with 
lighter forearm skin color will have lower 8-OHdG levels compared to those with darker 
forearm skin color, at baseline, and that individuals with higher skin exposure scores, as 
measured by the difference between exposed and unexposed skin colors, will have lower 
8-OHdG levels.  
Materials and methods: 
This clinical trial, assessed the effect of daily supplementation with 4000 and 
6000 IU of vitamin D3 over six months on biomarker of DNA/RNA oxidative stress 
among adults with type 2 diabetes living in South Florida. The parent study was 
conducted by Huffman et al. (20) assessing the effect of vitamin D3 supplementation on 
cardiovascular disease biomarkers. In the present study, serum samples collected at 
baseline, 3 months and 6 months stored at -80˚ʿ were used to measure DNA/RNA 
oxidative stress level (8-OHdG). 
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Study participants were recruited from 2 sources: 
- From community areas by distributing flyers including the purpose of the study, 
inclusion and exclusion criteria, and the investigators information.  
- From 2 clinics: Borinquen Health care center and Clinical Care Medical 
center.  Weekly visits were conducted to recruit study participants.  
Interested individuals called the investigators and expressed their willingness to 
participate in the study and were asked to answer a few pre-screening questions. 
Qualified individuals were invited for screening at the Human Nutrition Laboratory, 
Florida International University. After signing the informed consent form, fasting blood 
samples were collected and screening questionnaires were administered to evaluate 
whether the inclusion criteria were met (20).  
Inclusion criteria was being 30-70 years old, being African-American or Hispanic, 
having Type 2 diabetes, and being vitamin D insufficient [25(OH)D3 < 30 ng/mL]. 
Exclusion criteria was being pregnant or lactating, taking vitamin D supplements, 
injecting insulin, suffering from thyroid, hepatic and/or renal complications, suffering 
from HIV, or cancer. The duration of the intervention was 6 months and participants were 
contacted at four-time points: 
Time zero (T0): Screening: During screening the eligibility of the participants to 
enroll in the study was assessed based on the inclusion and exclusion criteria. Participants 
signed an informed consent form before the data collection. Fasting blood was collected 
for screening of vitamin D status. 
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Time one (T1): Baseline: All participants who met the inclusion criteria 
participated in the study. Blood collection, anthropometric measurements, skin color 
measurements, and a socio-demographic questionnaire were administered at baseline and 
vitamin D supplements (pills) were provided to the participants (4000 and 6000 IU/pill).  
Time two (T2): Blood collection, anthropometric measurements, and skin color 
measurements were administered after 3 months of supplementation with 4000 IU or 
6000 IU vitamin D3 pills. Additional vitamin D3 pills were provided to the participants. 
Time three (T3): Blood collection, anthropometric measurements, and skin color 
measurements were administered after 6 months of supplementation. Study was 
terminated at this point.  
Table 1. Parent Study Timeline 
Time Assessments 
Screening (T0) Informed consent form signing, fasting blood collection, screening 
questionnaire 
Baseline (T1) Fasting blood collection, sociodemographic questionnaire, food frequency 
questionnaire, skin color measurement, anthropometric measurement 
3 months (T2) 
 
Pill count, fasting blood collection, skin color measurement 
6 months (T3) 
 
Pill count, fasting blood collection, skin color measurement 
 
Measurements of variables: 
a. Socio-demographic questionnaire 
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A socio-demographic questionnaire was used to collect information about age, 
gender, race/ethnicity, years living in the United States and years having type 2 diabetes. 
b. Anthropometric measurements 
Height and weight measurements were taken by using a SECA balance scale 
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist 
circumference was measured by using a measuring tape to the nearest 0.1 cm. Systolic 
and diastolic blood pressure were measured in a sitting position by using an automated 
arm-cuff monitor. All measurements were done twice and the average of two readings 
was considered in the analysis. 
c. Skin color measurement 
Reflectance colorimetry method was used to determine skin color as an objective 
measure of skin sun exposure (IMS Smart Probe 400, Millford CT, USA) (20). This 
instrument uses the International Commission on Illumination Scale and ranges the skin 
color from 0 (black) to 100 (white). The measurement sites included 3 areas: wrist of the 
right hand as the most exposed area to sun, inside of the right upper arm and the waist as 
the least exposed areas to the sun (20). Each measurement was conducted 2 times and the 
average was considered in the proposed study analysis. This tool is validated by several 
studies (16, 20-21). Skin sun exposure level was determined by calculating the difference 
between the wrist of the right-hand skin color (the most exposed) and the inside of the 
right upper arm (the least exposed).  
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d. Food frequency questionnaire 
A validated short vitamin D and calcium questionnaire developed by Blalock (22) 
was used to assess the dietary calcium and vitamin D intakes. The modified questionnaire 
added pizza to the 22 existing foods and beverages and asked for serving size and 
frequency of consumption of each food (16). This tool is validated by several studies (16, 
20, 22). 
e. Physical activity 
Physical activity was measured using the Modifiable Activity Questionnaire 
(MAQ), which has been validated for individuals with type 2 diabetes (23-24). This 
questionnaire by Kriska et al. (25) measures the levels of leisure and occupational 
physical activity for over the past year in sum of hours per week. After collecting this 
information, the sum of hours per week were multiplied by the estimated metabolic rate 
to calculate metabolic equivalents (METs)/hours per week. 
f. Perceived stress 
Perceived stress level was measured by using Perceived Stress Scale (PSS-10) 
(26-27). The response categories in this questionnaire were ranged from ‘never’ = 0, 
‘almost never’ = 1, ‘sometimes’ = 2, ‘fairly often’ = 3, and ‘very often’ = 4. The total 
score outcome ranges from 0-40 which reflects perceived stress level. This questionnaire 
has been validated among individuals from different racial and ethnic groups, with and 
without type 2 diabetes (28). 
 
 
52 
g. Blood collection and analysis  
Fasting venous blood was collected by a certified phlebotomist (15 mL).  After 
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were 
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose 
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c 
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics 
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic 
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ) (16).  
h. Oxidative stress 
Oxidative stress biomarker, 8-hydroxyguanosine (8-OHdG), was assessed using a 
human DNA/RNA oxidative damage competitive enzyme-linked immunosorbent assay 
(Cayman Chemical, Ann Arbor, MI, item No 589320); this immunoassay measures the 
DNA/RNA damage by detecting 8-hydroxy-2`-deoxyguanosine and 8-hydroxyguanosine 
from DNA and RNA, respectively. In addition, it detects 8-hydroxyguanine from both 
DNA and RNA which provides more accurate information about biologic products of 
oxidative stress, compared to other available assays which mostly detect only one of the 
three biomarkers mentioned (29). As recommended by the assay protocol, initially 15 
serum samples were diluted with the assay buffer within the range of 1:25 - 1:100. After 
analyzing the results, dilution 1:50 was used for this study. Participant`s serum samples 
were defrosted and diluted with the assay buffer to 1:50. Assay standards were prepared 
in 8 test tubes by serially diluting the bulk standard from tube 1 to tube 8. Coated plates 
with goat polyclonal anti-mouse IgG were prepared with standards and serum samples 
based the assay protocol. Each standard and sample were run in duplicates. After addition 
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of DNA/RNA oxidative damage assay monoclonal antibody, plated were covered and 
incubated for 18 hours at 4°c. After completion of the incubation, plates were washed 5 
times with the assay wash buffer and were developed in dark with developing reagent for 
100 minutes on an orbital shaker. Each plate was read at 405 wavelengths using a plate 
reader located at Huffman Nutrition Laboratory at Florida International University. Data 
was plotted and analyzed using a pre-configured analysis tool for Cayman DNA/RNA 
oxidative damage ELISA kit.  
Statistical analysis: 
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago, 
IL, USA) was used for performing the statistical analysis. Descriptive statistics were 
conducted for baseline characteristics. Numerical normally distributed data and 
categorical data were compared using paired t-test and Chi-Squared test, respectively. 
The main outcome was serum 8-OHdG. Gender and time were input as categorical and 
the rest of variables were input as continuous in the analysis. G*Power 3.0.10 software 
was used for post-hoc power analysis. Mixed model was used to compare 4000 IU and 
6000 IU treatment groups. In this model, oxidative stress (8-OHdG) was the dependent 
variable and supplementation time was the independent variable. Covariates were age, 
gender, BMI, insulin level, HbA1c level, years with type 2 diabetes, perceived stress 
level, physical activity, and skin exposure score. Factors included gender and treatment 
groups. To compare the changes from baseline, three months and six months, Bonferroni 
multiple comparison test was used at the statistical significance of P-value <0.05.  
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Results 
Out of 92 individuals who were screened at baseline, 77 met the inclusion criteria 
and participated in the interventions. Two subjects were excluded due to missing values 
for sun exposure. Sixty-eight participants completed the study, females (n=41) and males 
(n=27), and were included in the present study`s analysis. Descriptive characteristics are 
featured in Table 2. Mean age was 54.94 ± 7.93 years. Mean years with type 2 diabetes 
was 6.44 ± 5.23 years. Oxidative stress (8-OHdG) was measured at baseline, after 3 
months and after 6 months. The unadjusted mean ± SD for 8-OHdG levels at baseline, 
after 3 months and after 6 months were 8068.94 ± 2158.13 pg/mL, 9462.22 ± 2403.89 
pg/mL, and 7412.69 ± 2031.68 pg/mL, respectively (Figure 1). Paired t-test comparisons 
showed a statistically significant change in 8-OHdG level between baseline and 3 months 
(P<0.001), 3 months and 6 months (P<0.001), and baseline and 6 months (P=0.013) 
(Figure 3). The unadjusted mean ± SD for serum 25(OH)D3 at baseline, after 3 months 
and after 6 months were 22.34 ± 6.67 ng/mL, 40.77 ± 13.63 ng/mL, and 40.41 ± 14.50 
ng/mL, respectively (Figure 2). Paired t-test comparisons showed a statistically 
significant change in 25OHD3 level between baseline and 3 months (P<0.001), and 
baseline and 6 months (P<0.001). There was no statistically significant difference in 
serum 25OHD3 between 3 months and 6 months of supplementations (Figure 3). 
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Figure 1. Mean DNA/RNA oxidative stress level (8-OHdG) at baseline, after 3 months, 
and after 6 months of supplementation with vitamin D3. Serum 8-OHdG level 
significantly increased after 3 months of supplementation with vitamin D3 and then 
significantly decreased after from 3 months to 6 months after supplementation with 
vitamin D3. * Statistically significance from baseline. † Statistically significant from 3 
months. P< 0.05 is considered significant.  
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Figure 2. Mean serum vitamin D3 level [25(OH)D3] at baseline, after 3 months, and after 
3 months of supplementation with vitamin D3. * Statistically significance from baseline. 
P< 0.05 is considered significant. 
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Figure 3. Mean DNA/RNA oxidative stress level (8-OHdG) and mean serum 25(OH)D3 
at baseline, after 3 months, and after 6 months of supplementation with vitamin D3. * 
Statistically significance from baseline. † Statistically significant from 3 months. P< 0.05 
is considered significant.  
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There were 46 participants in the 4000 IU/day intervention group and 22 
participants in the 6000 IU intervention group. The unadjusted mixed model showed no 
significant differences between the 4000 IU and 6000 IU groups regarding the oxidative 
stress level and the interactions between time and treatment were not significant. The 
model showed a statistically significant increase in 8-OHdG level between baseline and 3 
months (P<0.001), but a significant decrease between 3 months and 6 months (P<0.001), 
and baseline and 6 months (P=0.016) (Table 3).   
After adjusting for age, gender, BMI, insulin level, HbA1c level, years with type 
2 diabetes, perceived stress, physical activity, and skin sun exposure level, the model 
remained statistically significant; Pairwise comparisons showed significant changes in 8-
OHdG level between baseline and 3 months (P<0.001), between 3 months and 6 months 
(P<0.001), and between baseline and 6 months (P=0.020) (Table 4). 
There were no significant correlations between exposed and unexposed skin color 
(forearm, upper-arm, and stomach) and the oxidative stress level at baseline, 3 months 
and 6 months. In addition, no statistically significant relations were found between skin 
sun exposure (difference between the exposed and unexposed skin color) and oxidative 
stress level at baseline, 3 months and 6 months. No adverse events associated with 
supplementation were reported by any of the study arms during the 6-month period of 
participation.  
Discussion 
To our knowledge this was the first interventional study among human subjects 
with type 2 diabetes investigated the effect of long-term supplementation of different 
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dosages of vitamin D3 on the biomarker of DNA/RNA oxidative stress, 8-OHdG. The 
results of the present study suggest daily supplementation with vitamin D3, both 4000 IU 
and 6000 IU, for 6 months may improve the DNA/RNA oxidative stress status among a 
group of individuals with type 2 diabetes and vitamin D deficiency/insufficiency. The 
improvement remained significant after adjusting for age, gender, BMI, insulin level, 
hemoglobin A1C level, years with type 2 diabetes, perceived stress level, physical 
activity, and skin exposure score.  
In contrast with our study, Nikooyeh et al. (30) reported that daily intake of 
vitamin D fortified yogurt drink for 12 weeks decreased biomarkers of oxidative stress 
among 90 of individuals with type 2 diabetes. Different from our study, the daily vitamin 
D3 supplementation for this study was significantly lower (500 IU vs 4000/6000 IU), and 
the baseline serum vitamin D level among their participants was 44.8 ± 28.7 ng/mL, 
which was above the sufficient level of 30 ng/mL (30).  
The dissimilarities in design between the two studies may explain why we could 
not detect improvement in oxidative stress status for the first 3 months of the study. As 
evidenced by our results, decrease in oxidative stress level occurred only after study 
subjects reached the sufficient serum 25(OH)D3 level (>30 ng/mL). Therefore, although 
oxidative stress was increasing from baseline to 3 months, we observed a significant 
decrease in oxidative stress between 3 months and 6 months with daily supplementation 
of vitamin D3. In fact, the mean 8-OHdG at 6 months was significantly lower than the 
mean 8-OHdG at both baseline [8068.94 ± 2158.13 pg/mL to 7412.69 ± 2031.68 pg/mL 
(P=0.013)] and 3 months [9462.22 ± 2403.89 pg/mL to 7412.69 ± 2031.68 pg/mL 
(P<0.001)]. This may suggest the beneficial effects of vitamin D3 supplementation on 
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oxidative stress under diabetes conditions may be observed after the replenishment of 
serum vitamin D. Therefore, our findings suggest that longer duration of vitamin D3 
supplementation is needed among individuals with type 2 diabetes and vitamin D 
deficiency/insufficiency. 
The outcome of another longitudinal study among 103 patients with type 2 
diabetes and vitamin D deficiency, which aimed to evaluate the effect of vitamin D3 
supplementation on oxidative stress (31) showed weekly supplementation with 60,000 IU 
of vitamin D3 for 8 weeks could improve oxidative stress level among individuals with 
type 2 diabetes and vitamin D deficiency. Participants consumed 4 sachets of 
cholecalciferol with 120 ml of milk every week for 4 weeks. The mean serum 25(OH)D 
at baseline was 14.6 ng/mL and was significantly increased to 42.33 ng/mL (P<0.001) 
after the 8 weeks of intervention with this larger doses. Although both studies are in 
agreement that vitamin D3 supplementation significantly improves the oxidative status 
among individuals with type 2 diabetes and vitamin D deficiency, in our study we could 
find improvement in oxidative stress status only after 6 months of intervention. This may 
be due to significantly higher dosage of supplementation (equivalent to 8571/day IU) in 
the Anansabaskar et al. (31) compared with our daily supplementation of 4000 IU or 
6000 IU of vitamin D in our study.  
Several other studies among human subjects also revealed that vitamin D 
supplementation may have beneficial effects on oxidative stress status (32, 33). In a 
randomized double-blind placebo-controlled trial among 104 female subjects with 
vitamin D deficiency and polycystic ovary syndrome, weekly supplementation with 
50,000 IU of vitamin D for 8 weeks improved the biomarkers of oxidative stress (32). In 
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another study among 53 adults with non-alcoholic fatty liver disease, Sharifi et al. (33) 
reported oral supplementation with 50,000 IU of vitamin D3 every 14 days for 4 months 
improved serum 25(OH)D3 status as well as biomarkers of oxidative stress. The present 
study did not find a significant association between serum 25(OH)D3 and 8OHdG. This 
may be due to small sample size of the current study and low power. 
Animal studies suggest an antioxidant role for vitamin D. Konko et al. (34) 
showed that vitamin D analog could reduce oxidative stress in non-obese type 2 diabetic 
rats as measured by 8-OHdG. It has been suggested that vitamin D induced decrease in 
oxidative stress determines the vasoprotective properties of vitamin D. Administration of 
paricalcitol, a vitamin D receptor antagonist, could improve pancreatic oxidative stress in 
type 2 diabetic rats (35). It has been concluded that vitamin D may protect B cells from 
damages caused by ROS and therefore may prevent B cell dysfunction and apoptosis 
(35). In rats with alloxan-induced diabetes, vitamin D administration could increase the 
antioxidant activities of enzymes and decrease oxidative stress, especially in the 
pancreatic tissue (36). This study suggested a therapeutic role for vitamin D in diabetes 
condition. 
Conclusion 
The results of the present study implied daily oral supplementation with higher 
doses of vitamin D, 4000 IU and 6000 IU/day, for 6 months may improve oxidative stress 
status among a group of individuals with type 2 diabetes and vitamin D 
deficiency/insufficiency. It also showed that there were no significant differences 
between the lower and higher doses on the effect on oxidative stress. Neither arm 
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reported adverse effects of supplementation during the six months of participation, 
therefore, both doses were considered safe.  Furthermore, 8-OHdG may be a predictive 
biomarker of DNA/RNA damage among individuals with type 2 diabetes. The limitations 
of this study included lack of a control group, small samples size, and exclusion of 
participants with sufficient serum vitamin D levels. The strengths of the study were the 
ability to compare 2 different dosages of vitamin D3 supplementation, the longevity of 
study and measurement of sun exposure. We did not find significant changes in sun 
exposure during the 6-month period of this study. Further interventional studies among 
human subjects with larger sample sizes and longer observation timelines are required to 
confirm the antioxidants effects of vitamin D on RNA/DNA oxidative stress.  
 
 
 
 
 
 
 
 
 
 
 
63 
Table 2. Participants characteristics at baseline (N = 68) 
Variable          Mean ± SD   
          N= 68 
Age (years)  
Gender n (%) 
   Female 
   Male 
Dosage n (%) 
   4000 IU                                                                                                                                                   
   6000 IU 
54.94 ± 7.93 
 
41 (60) 
27 (40) 
                                 
46 (68)
                               22 (32)          
BMI (Kg/m2)  33.7 ± 6.59 
Years with T2DM 6.44 ± 5.23 
Forearm skin color 
Upper-arm skin color  
Skin exposure score 
55.29 ± 7.49 
59.87 ± 8.66 
4.58 ± 4.27 
Physical activity (METs/hour/week) 
 
14.65 ± 25.68 
     Data are % or mean ± standard deviation (SD). IU = International Unit. BMI = Body  
     mass index. Sun exposure is defined by calculating the difference between quantitative 
     measures of forearm skin color and upper-arm 
     skin color. METs = Metabolic equivalents. 
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Table 3. Mixed model comparisons of repeated measures at baseline, after 3 months and 
after 6 months without adjustment for covariates. 
               Variable        Mean ± SE 
          (N= 68) 
        P-value 
8-OHdG (pg/mL) 
Baseline 
3 months 
6 months 
  
8014.86 ± 277.19 
9649.95 ± 302.467 
7338.26 ± 260.12 
  
  
*0.001 
*0.016, †0.001 
25(OH)D (ng/mL)  
Baseline                                        
3 months 
6 months 
 
22.41 ± 0.87 
  42.35 ± 1.67 
 41.14± 1.87 
  
  
*0.001 
*0.001 
Data represented by mean ± standard error. * Statistically significance from baseline.  
† Statistically significant from 3 months. P-values are from multiple comparisons with 
Bonferroni correction. P<0.05 is considered significant. Time and dosage interactions 
were not significant for any of the variables. 
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Table 4. Mixed model comparisons of repeated measures at baseline, after 3 months and 
after 6 months with adjustment for covariates (N = 68). 
                     Mean ± SD 
(N= 68) 
*P-value 
8-OHdG (pg/mL) 
Baseline 
3 months 
6 months 
 
      8064.905 ± 266.12 
                  9677.06 ± 278.45 
      7395.60 ± 253.64 
 
 
*0.001 
*0.020, †0.001 
Data represented by mean ± standard error. * Statistically significance from baseline.  
† Statistically significant from 3 months. P-values are from multiple comparisons with 
Bonferroni correction. P<0.05 is considered significant. Time and dosage interactions 
were not significant for 8-OHdG. Mixed model analysis was adjusted for age, gender, 
BMI, insulin level, HbA1C level, years with type 2 diabetes, perceived stress level, 
physical activity, and skin exposure score. 
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CHAPTER IV: EFFECT OF VITAMIN D3 SUPPLEMENTATION ON 
GLYCATED ALBUMIN IN ADULTS WITH TYPE 2 DIABETES 
Introduction 
Diabetes mellitus is ranked as the seventh leading cause of death in the United 
States (1). According to the 2014 National Diabetes Statistics Report by the Centers for 
Disease Control and Prevention (CDC), over 29 million individuals (9.3% of the U.S 
population) were diagnosed with diabetes while more than 8 million cases remained 
undiagnosed (2). Type 2 diabetes accounts for 90-95% of all diagnosed diabetes cases 
among adults.  
Type 2 diabetes and early glycation products 
Persistent hyperglycemia leads to non-enzymatic glycation of proteins, known as 
Maillard reaction. In this reversible process, the carbonyl group of reducing sugars, such 
as glucose, binds to the amino group on lysine residues of proteins, such as hemoglobin, 
and form early glycation products known as Schiff-bases and Amadori adducts (3). Early 
glycation leads to formation of intermediate glycation products (IGPs) such as glycated 
hemoglobin (HbA1c) and glycated albumin (GA). Continuous elevation in IGP levels can 
lead to their irreversible rearrangement to stable advanced glycation end products (AGEs) 
(3-4). AGEs accumulation is a measure of carbonyl, metabolic and oxidative stress and 
serve as a long term metabolic memory, rather than short term glycemic control. In 
contrast, IGPs are better indicators of glycemic control (4). Amadori adducts, the major 
form of IGPs, have 2-3 times higher concentrations of glycated products than AGEs (5). 
HbA1c is currently an established gold standard Amadori adduct, reflecting the glycemic 
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control over the period of 8-12 weeks. In addition, HbA1c is associated with the risk of 
chronic diabetes related complications such as neuropathy, nephropathy, retinopathy and 
coronary artery disease (5-6). HbA1c level, however, can be affected by several factors 
such as red blood cells turnover, uremia, erythropoietin treatment, blood transfusion, 
anemia, renal malfunction, and iron-deficiency (5). Based on the twin studies by Sneider 
et al. (7), HbA1c is strongly inherited and influenced by genetics. Furthermore, HbA1c 
reflects on the glycemic control inside the RBCs while serum protein glycation reflects 
glycemic control in the extracellular space (8). 
Albumin is the most abundant protein in plasma and makes more than 50% of 
plasma proteins (9). With a half-life of 14-21 days, albumin is known as the main 
extracellular antioxidant and plays a fundamental role in maintaining oxidative balance 
(10). Furthermore, albumin has anti-inflammatory and anti-thrombotic properties and 
plays a crucial role in transportation of nutrients, metabolites, hormones and drugs while 
maintaining the osmotic pressure (5).  As a lysine rich protein with 59 lysine residues, 
albumin is widely involved in extracellular Maillard reactions under hyperglycemic 
conditions (5). Non-enzymatic glycation of albumin happens 10 times faster and 9 times 
more than non-enzymatic glycation of hemoglobin in-vivo (11). It is suggested that 
glycated albumin (GA) may be a more accurate indicator of short term glycemic control 
among individuals with type 1 and type 2 diabetes (12). GA have been linked to diabetes 
induced complications including nephropathy, neuropathy and arteriosclerosis (9). 
Although as compared to hemoglobin, serum albumin is less affected by RBC turnover, 
erythropoietin treatment, blood transfusion, anemia, and iron-deficiency; albumin 
turnover, hepatic cirrhosis and renal malfunction can enhance serum albumin level. It is 
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suggested GA/HbA1c ratio may be a better index of glycemic control among individuals 
with diabetes (12).  
Fructosamine is the measure of a combination of circulating glycated proteins, 
such as glyco-lipoproteins and glyco-globlulins (13-14). Knowing that albumin is the 
most abundant protein in serum, fructosamine is predominately reflecting GA, however, 
GA% may provide a more accurate and efficient measure of extracellular glycation status 
over 2-3 weeks (14). Furthermore, in case of abnormal albumin levels, fructosamine 
values must be adjusted to albumin levels (14).   
Oxidative Stress, Inflammation and Glycated Albumin 
Albumin structure and antioxidant function is greatly suppressed by the Maillard 
reaction. Amadori GA is in fact a stimulant for oxidative stress by producing oxygen free 
radicals and lipid peroxides. Non-enzymatic glycation of albumin also suppresses its 
nutrient/metabolite/drug binding affinity and diminishes its transportation ability (10). In 
macrophage RAW 246.7 cells (a commercial murine cell-line), GA induced oxidative 
stress activated extracellular signal-regulated kinase (ERK), influenced TGF-β1 
production and activated NF-κB which plays a critical regulatory role in immunity and 
inflammatory responses (15). In diabetic human endothelial cells, GA increased oxidative 
stress and Reactive Oxygen Species (ROS) production by up-regulating nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase (16).  This may help to understand the 
role of Amadori-adducts in pathogenesis of diabetes-induced vascular complications. 
Exposure of diabetic mice adipocytes to GA resulted in increased oxidative stress, 
accumulation of ROS in these cells and oxidation of proteins inside them (17). GA-
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derived glycation end products (AGEs) may lead to adipocytes dysfunction and insulin 
resistance in adipose tissue. 
Type 2 diabetes and Vitamin D 
It has been shown that both, vitamin D deficiency and type 2 diabetes, have 
several risk factors in common: aging, being overweight, having a sedentary lifestyle, and 
being African-American or Hispanic (18). In addition, seasonal variations have been 
observed for both serum vitamin D [25(OH)D3] levels and insulin concentrations 
suggesting a potential relationship between serum 25(OH)D3 and development of type 2 
diabetes (19-21). Vitamin D directly affects insulin sensitivity, Beta cell function, insulin 
secretion and hence mediates glucose homeostasis (18). Several studies reported an 
association between lower serum vitamin D levels and increased risk of developing type 
2 diabetes (22-24). In addition, a high prevalence of hypovitaminosis D has been 
observed among individuals diagnosed with type 2 diabetes, compared to individuals 
without type 2 diabetes (25). Beside its effect on Beta cell function and insulin 
sensitivity, vitamin D also regulates calcium homeostasis which plays an important role 
in regulating insulin secretion (26).  
An extensive review with a meta-analyses, proposed that the direct role of vitamin 
D on glucose homeostasis is mediated via binding of its metabolically active form, 
1,25(OH)2D3, to the vitamin D receptors (VDR) in pancreatic Β-cells, activation of 
25(OH)D3 to 1,25(OH)2D3 by the enzyme 1-α-hydroxylase (expressed in B-cells) within 
B-cells, stimulating the insulin receptor gene transcription, enhancing the expression of 
insulin receptor and hence affecting the insulin-mediated glucose transport (20). VDRs 
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also exist in skeletal muscle and adipose tissues which are insulin targets and are 
responsible for peripheral insulin sensitivity. VDR expression in human skeletal muscle 
tissue, which declines with age, stimulates regulation of protein synthesis and results in 
diminished insulin sensitivity among older adults (27). In addition, animal studies 
showed impaired insulin secretion in mice with inactive VDRs (28). 
The indirect role of vitamin D in glucose homeostasis is determined by its effect 
on regulation of extracellular calcium and calcium flux in the pancreatic B-cells (20). 
Imbalance between the extracellular and intracellular calcium pools influences the ability 
of B-cells to release insulin. Serum vitamin D concentration is inversely associated with 
Parathyroid hormone (PTH) level, which regulates intracellular calcium (29). In animal 
and in-vitro study, hypovitaminosis D was found to cause augmented PTH levels, which 
resulted in elevated intracellular calcium levels (30). In adipose tissue (an insulin target 
tissue), sustained augmentation in cytosolic calcium level was associated with increased 
insulin resistance (30). The insulin mediated glucose uptake was decreased by 30% 
among PTH injected rats (30). This could be due to increased phosphorylation of GLUT-
4 (an insulin-regulated glucose transporter in adipose and muscle tissue) in the presence 
of elevated cytosolic calcium levels. Cross-sectional studies reported an inverse relation 
between serum vitamin D level and insulin sensitivity (31-33). In addition, vitamin D and 
calcium supplementation attenuated insulin resistance among non-diabetic older adults 
with impaired fasting plasma glucose (FPG) (34). 
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Vitamin D and Glycated Albumin  
The relationship between vitamin D and GA is yet to be studied. Furthermore, to 
our knowledge no studies have yet investigated the effectiveness of vitamin D3 
supplementation on GA, as a biomarker of short-term glycemic control, among 
individuals with or without diabetes. Despite lack of evidence on the relationship 
between GA and vitamin D, HbA1c have been negatively linked to serum 25(OH)D level 
(35-37). Clinical trials on vitamin D supplementation and its impact on glycemic 
improvement (specifically on HbA1c) among individuals with type 2 diabetes, however, 
could not consistently support the effectiveness of vitamin D supplementation on 
glycemic control (38). It is not clear whether improvement in serum vitamin D may 
improve Amadori formation of GA. We assume vitamin D may improve GA level via its 
antioxidant properties. Furthermore, since vitamin D has a high binding affinity for 
adipose tissue, it may prevent the GA-induced oxidative stress in adipocytes via its 
antioxidant capabilities. Albumin is a transporter of vitamin D; therefore, binding of 
vitamin D to serum albumin may affect its affinity to glucose under non-enzymatic 
conditions. In that case, vitamin D may be effective in prevention of GA-derived AGEs 
production. 
Significance of the current study 
To our knowledge, there is currently no studies that assessed the possible effects 
of vitamin D3 supplementation on serum GA levels among individuals with or without 
type 2 diabetes. While GA is a relatively new biomarker for type 2 diabetes management, 
almost all the current studies on vitamin D supplementation in type 2 diabetes have been 
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targeting fasting plasma glucose and HbA1c as the markers of glycemic control. The 
findings from this study will help to fill the gap on the possible beneficial effects of 
vitamin D3 on GA, as the most abundant Amadori-protein in human serum. Therefore, 
the aim of this is study was to investigate and compare the effectiveness of daily 
supplementation with 4000 IU and 6000 IU vitamin D3 for 3 months and 6 months on 
GA. 
Materials and methods: 
In this clinical trial, we assessed the effect of daily supplementation with 4000 
and 6000 IU of vitamin D3 over six months on glycated albumin (GA), albumin (ALB) 
and GA% (GA to ALB ratio * 100) among adults with type 2 diabetes living in South 
Florida. The parent study was conducted by Huffman et al. (39) assessing the effect of 
vitamin D3 supplementation on cardiovascular disease biomarkers. In the present study, 
serum samples were collected at baseline, 3 months and 6 months stored at -80˚ʿ were 
used for measuring GA, ALB and GA%. 
Study participants were recruited from 2 sources: 
- From community areas by distributing flyers including the purpose of the study, 
inclusion and exclusion criteria, and the investigators information.  
- From 2 clinics: Borinquen Health care center and Clinical Care Medical 
center.  Weekly visits were conducted to recruit study participants.  
Interested individuals called the investigators and expressed their willingness to 
participate in the study and were asked to answer a few pre-screening questions. 
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Qualified individuals were invited for screening at the Human Nutrition Laboratory, 
Florida International University. After signing the informed consent form, fasting blood 
samples were collected and screening questionnaires were administered to evaluate 
whether the inclusion criteria were met (39).  
Inclusion criteria were being 30-70 years old, being African-American or 
Hispanic, having Type 2 diabetes, being vitamin D insufficient [25(OH)D3 < 30 ng/mL]. 
Exclusion criteria was being pregnant or lactating, taking vitamin D supplements, 
injecting insulin, suffering from thyroid, hepatic and/or renal complications, suffering 
from HIV, cancer. The duration of the intervention was 6 months and participants were 
contacted at four time points: 
Time zero (T0): Screening: During screening the eligibility of the participants to 
enroll in the study was assessed based on the inclusion and exclusion criteria. Participants 
signed an informed consent form before the data collection. Fasting blood was collected 
for screening of vitamin D status. 
Time one (T1): Baseline: All participants who met the inclusion criteria 
participated in the study. Blood collection, anthropometric measurements, skin color 
measurements, and a socio-demographic questionnaire were administered at baseline and 
vitamin D supplements (pills) were provided to the participants (4000 and 6000 IU pills).  
Time two (T2): Blood collection, anthropometric measurements, and skin color 
measurements were administered after 3 months of supplementation with 4000 IU or 
6000 IU vitamin D3 pills. Additional vitamin D3 pills were provided to the participants. 
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Time three (T3): Blood collection, anthropometric measurements, and skin color 
measurements were administered after 6 months of supplementation. Study was 
terminated at this point.  
Measurements of variables: 
a. Socio-demographic questionnaire 
A socio-demographic questionnaire was used to collect information about age, 
gender, race/ethnicity, years living in the United States and years having type 2 diabetes. 
b. Anthropometric measurements 
Height and weight measurements were taken by using a SECA balance scale 
(SECA Corp, Columbia, MD), to the nearest 0.5 cm and 0.1 kg, respectively. Waist 
circumference was measured by using a measuring tape to the nearest 0.1 cm. All 
measurements were done twice and the average of two readings was considered in the 
analysis. 
c. Skin exposure measurement 
Reflectance colorimetry method was used to determine skin color as an objective 
measure of skin sun exposure (IMS Smart Probe 400, Millford CT, USA) (39). This 
instrument uses the International Commission on Illumination Scale and ranges the skin 
color from 0 (black) to 100 (white). The measurement sites included 3 areas: wrist of the 
right hand as the most exposed area to sun, inside of the right upper arm and the waist as 
the least exposed areas to the sun (39). Each measurement was conducted 2 times and the 
average was considered in the proposed study analysis. This tool is validated by several 
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studies (39-40). Skin sun exposure level was determined by calculating the difference 
between the wrist of the right hand skin color (the most exposed) and the inside of the 
right upper arm (the least exposed). 
d. Blood collection and analysis  
Fasting venous blood was collected by a certified phlebotomist (15 mL).  After 
coagulation of blood samples in serum separator tubes for 30-45 minutes, samples were 
centrifuged at 2500 RPM for 30 minutes to obtain the serum. Fasting plasma glucose 
concentration was measured by hexokinase enzymatic method, glycated hemoglobin A1c 
(HbA1c) was measured by using DCA2000 + system (BAYER Corporation, Diagnostics 
Division, N.Y) and 25(OH)D3 concentrations were measured by using an enzymatic 
immunoassay kit (Immunodiagnostic Systems Scottsdale, AZ) (16). C-reactive protein 
(CRP) was measured Immulite (Diagnostic Products Corporation, Los Angeles, CA). 
Insulin was determined by an enzymatic immunoassay kit (Millipore, St Charles, MZ). 
e. Glycated albumin, albumin and GA% 
Serum GA, ALB and GA% were measured by using GLYCABEN assay (Exocell 
Inc., Philadelphia, PA, item No 1003). In this sandwich based enzyme linked 
immunosorbent assay, glycated albumin is quantitatively determined by capturing the 
binding of a specific immobilized monoclonal antibody, A717, to glycated albumin (41-
42). In this process, 100 μL of participants’s serum samples were mixed with 100 μL 
Charcoal Extraction Buffer overnight (18-hours) at room temperature. After centrifuging 
the mixture at 14K for 10 minutes, 100 μL of the supernatant were collected. To 
neutralize the extracted serum samples, 100 μL Glycated Albumin Neutralizing Buffer 
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were added to the collected samples and mixed. Samples were centrifuged at 14K for 1 
minute.  
To measure GA, the precoated Glycated Albumin Assay Plate was washed 8 
times with wash buffer. Assay standards were prepared as instructed in the GLYCABEN 
protocol. Then 50 μL Glycated Albumin Reaction Buffer was added to all the wells. 
After adding 50 μL Glycated Albumin Diluent to the blank wells, 50 μL of assay 
standards and assay control were added to the designated wells. Later, 50 μL of the 
extracted and neutralized serum samples were added to the plate. Plate was incubated in 
an incubation chamber at room temperature for 60 minutes. The plate was washed 8 
times and 100 μL of TMB color developer was added to all the wells. After 10 minutes of 
incubation at room temperature, 100 μL Acid Color Stopper was added to the wells. The 
absorbance was determined at 450 nm by a plate reader located at Huffman Nutrition 
Laboratory at Florida International University. Regression analysis was used to determine 
the glycated albumin in each sample. Concentrations were expressed as mg/mL. 
To measure total albumin (ALB), serial dilution of total albumin standards were 
prepared as instructed in the GLYCABEN protocol. A non-coated plate was used for this 
colorimetric assay. After adding 10 μL of purified water in the blank wells, 10 μL of the 
standards were added to the standard well. Later, 10 μL of the extracted and neutralized 
serum samples were added to the designated wells followed by 200 μL of Total Albumin 
Reagent to all the wells. After 5 minutes incubation in the room temperature, the 
absorbance was determined at 630 nm by a plate reader. Regression analysis was used to 
determine the albumin levels. Concentrations were expressed as mg/mL. 
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GA% was calculated by dividing the absolute concentration of GA (mg/mL) to 
the total albumin concentration (mg/mL) multiplied by 100: 
GA% = GA/ALB x 100% 
Expected values measured by Glycaben for GA% for non-diabetic individuals is 
estimated between 0.4% to 2.4%. For individuals with uncontrolled diabetes, GA% will 
be >2.5%. 
Statistical analysis: 
The IBM statistical package for the social sciences (SPSS) version 20 (Chicago, 
IL, USA) was used for performing the statistical analysis. Descriptive statistics were 
conducted for baseline characteristics. Numerical normally distributed data and 
categorical data were compared using paired t-test and Chi-Squared test, respectively. 
The main outcome was GA%. Gender and time were input as categorical and the rest of 
variables were input as continuous in the analysis. G*Power 3.0.10 software was used for 
post-hoc power analysis. Mixed models were used to compare 4000 IU and 6000 IU/day 
treatment groups. In this model, GA% was the dependent variable and supplementation 
time was the independent variable. Covariates were age, BMI, sun exposure, fasting 
plasma glucose, insulin and CRP. Factors included gender and treatment groups. To 
compare the changes from baseline, three months and six months, Bonferroni multiple 
comparison test was used at the statistical significance of P-value <0.05.  
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Results 
Seventy-seven out of 92 subject who were initially screened for this study, met 
the inclusion criteria. Two participants were excluded due to missing values for sun 
exposure. Sixty-eight participants completed the study. Values were tested for normal 
distribution. Three subjects with outlier values for GA and ALB were excluded. A 
sample of 65 participants, females (n = 40) and males (n = 25), were included in the 
present study`s analysis. There were 44 participants in 4000 IU intervention group and 21 
participants in the 6000 IU intervention group. Mean age was 54.52 ± 7.86 years. Mean 
FPG at baseline, 3 months and 6 months were 186.478 ± 79.93, 184.52 ± 72.55, and 
172.8 ± 71.4 mg/dL. There were no statistically significant differences in FPG from 
baseline to 3 months (P=0.756), 3 months to 6 months (P=0.084) and baseline to 6 
months (P=0.142).  Mean HbA1c at baseline, 3 months and 6 months were 8.41 ± 2.31, 
8.37 ± 2.03, and 8.30 ± 2.06 mg/dL. There were no statistically significant differences in 
HbA1c from baseline to 3 months (P=0.806), 3 months to 6 months (P=0.701) and 
baseline to 6 months (P=0.635). Mean insulin levels at baseline, 3 months and 6 months 
were 12.63 ± 11.56, 11.64 ± 7.17, and 11.3 ± 7.35 mg/dL. There were no statistically 
significant differences in insulin levels from baseline to 3 months (P=0.474), 3 months to 
6 months (P=0.687) and baseline to 6 months (P=0.256). Mean CRP at baseline, 3 
months and 6 months were 8.07 ± 10.81, 6.81 ± 7.3, and 7.13 ± 6.91 mg/dL. There were 
no statistically significant differences in CRP from baseline to 3 months (P=0.271), 3 
months to 6 months (P=0.701) and baseline to 6 months (P=0.425).  
Unadjusted mean ± SD for serum 25(OH)D3 at baseline, 3 months and 6 months 
were 22.4 ± 6.77, 40.4 ± 13.68, and 40.57 ± 14.55, respectively. Paired t-test analysis 
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showed a statistically significant increase in 25(OH)D3 from baseline to 3 months 
(P<0.001), and from baseline to 6 months (P< 0.001). There were no significant 
differences between 25(OH)D3 levels at 3 months and 6 months (P=0.886). Mixed model 
analysis did not show significant interactions between 2 intervention groups and study 
time points regarding 25(OH)D3. Unadjusted mean ± SD for GA at baseline, 3 months 
and 6 months were 1.51 ± 0.44, 1.47 ± 0.72, and 1.54 ± 0.34, respectively (Table 1). 
Paired t-test analysis showed no statistically significant differences between GA levels at 
baseline and 3 months (P=0.418), 3 months and 6 months (P=0.112), and baseline and 6 
months (P=0.619). Mixed model analysis controlling for interactions between 4000 IU 
and 6000 IU/day doses and outcome variables showed no differences between the two 
treatment groups. Unadjusted mean ± SD for ALB at baseline, 3 months and 6 months 
were 32.84 ± 05.69, 36.34 ± 7.36, and 35.66 ± 6.7, respectively (Table 1). Paired t-test 
analysis showed statistically significant differences between ALB levels at baseline and 3 
months (P=0.002), and at baseline and 6 months (P=0.009). There were no significant 
differences between ALB levels at 3 months and 6 months (P=0.521).  Mixed model 
analysis controlling for interactions between 4000 IU and 6000 IU doses and outcome 
variables showed no differences between the two treatment groups. Unadjusted pairwise 
comparisons between ALB levels showed a statistically significant increase from baseline 
to 3 months (P=0.003), and a statistically significant increase from baseline to 6 months 
(P=0.031). After adjusting for covariates, including age, gender, BMI, sun exposure, 
fasting plasma glucose, insulin and CRP, the model remained statistically significant for 
baseline and 3 months (P=0.004) and baseline and 6 months (P=0.046). 
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Unadjusted mean ± SD for GA% at baseline, 3 months and 6 months were 4.69 ± 
1.7, 4.13 ± 1.09, and 4.42 ± 1.23, respectively. Paired t-test analysis showed statistically 
significant differences between GA% at baseline and 3 months (P= 0.005). This 
difference was not statistically significant for GA% at 3 months and 6 months (P= 0.068) 
and GA% at baseline and 6 months (P= 0.208). Mixed model analysis controlling for 
interactions between 4000 IU and 6000 IU/day doses and outcome variables showed no 
differences between the two treatment groups. Unadjusted pairwise comparisons between 
GA% were statistically significant from baseline to 3 months (P=0.015), and from 3 
months to 6 months (P=0.039), but not from baseline to 6 months (P= 0.488). After 
adjusting for covariates, including age, gender, BMI, sun exposure, fasting plasma 
glucose, insulin and CRP, the change remained statistically significant for baseline and 3 
months (P= 0.018) but not for 3 months to 6 month (P= 0.069), nor for baseline and 6 
months (P= 0.471). 
Discussion 
To our knowledge the present study is the first to assess the effects of vitamin D3 
supplementation on serum glycated albumin (GA%) among human subjects with or 
without type 2 diabetes. Most of the previous studies investigated the effects of vitamin 
D3 on HbA1c (38, 43-51). The results of the present study showed that daily 
supplementation with 4000 IU and 6000 IU of vitamin D3 to individuals with type 2 
diabetes could significantly increase serum 25(OH)D3 after 3 months (P< 0.001). 
However, after reaching the sufficient level of vitamin D level (>20 ng/mL) in 3 months, 
the same dose of supplementation could not significantly change serum 25(OH)D3 from 
3 months to 6 months. We observed the same change pattern for GA%. GA% is a 
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relatively new biomarker of glycemic control and oxidative stress. GA half-life is shorter 
than HbA1c (2-3 weeks for GA% compared to 2-3 months for HbA1c) and it is believed 
to be a more sensitive biomarker of glycemic status compared to HbA1c. Our results 
showed a statistically significant decrease in GA% after 3 months of supplementation 
with vitamin D3, with both 4000 IU and 6000 IU/day dosages. However, from 3 months 
to 6 months, there was a significant increase in GA%. Furthermore, the present study did 
not find a significant association between serum 25(OH)D3 and GA%. This may be due 
to small sample size of the current study and low power.  
Overall, we could not detect a significant change in GA% from baseline to 6 
months. This is consistent with our findings regarding HbA1c; we could not find a 
statistically significant change in HbA1c with vitamin D3 supplementation over 6 months 
(nor for 3 months). Madar et al (38) also reported no significant improvements in HbA1c 
and fructosamine after 16 week of vitamin D3 supplementation to healthy individuals 
with insufficient vitamin D levels. In this randomized double-blinded placebo-controlled 
study in Norway, 251 immigrants aged 18-50 years were assigned to receive 400 IU (n = 
85), 1000 IU (n = 84), or placebo (n = 82). Although we found similar results with 
HbA1c and GA% over 6 months of oral supplementation with higher doses of vitamin 
D3, we found significant decrease in GA% from baseline to 3 months. There were several 
differences in design between our study and Madar et al. (38). Madar’s did not measure 
fructosamine levels after 3 months of supplementation with vitamin D. This trial was 
conducted among a younger group of individuals without type 2 diabetes. Comparing 
GA% with fructosamine, it is believed that GA% is a more sensitive diagnostic tool than 
fructosamine (13). Furthermore, knowing fructosamine is predominantly a measure of 
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GA, adjustment for abnormal albumin levels should be considered to obtain accurate 
measures of nonenzymatic glycation of extracellular proteins.  
A recent systematic review of 12 interventional and 7 observational studies on the 
effect of vitamin D on type 2 diabetes reported that there is not sufficient evidence 
supporting the beneficial effects of vitamin D supplementation on glycemic control 
among patients with type 2 diabetes (43), this conclusion was reached despite cumulative 
evidence on the direct and indirect role of vitamin D in glucose metabolism and the 
established association between serum vitamin D status and glycemic status. More 
specifically, the systematic review concluded that daily supplementation with lower than 
6000 IU/day vitamin D (38, 44-45), supplementation with 400-5600 IU/day vitamin D for 
less than 6 months (38, 46), and supplementation with vitamin D among individuals with 
well-managed type 2 diabetes or sufficient serum vitamin D levels did not improve 
biomarkers of glucose metabolism (43). In contrast; we found significant improvement in 
GA% in the first phase of study (baseline to 3 months), when participants had 
hypovitaminosis D. When participants reached the sufficiency level (> 20 ng/mL) at 3 
months, there were no further improvements in GA% from 3 months to 6 months.  
It has been suggested that supplementation with more than 4000 IU of vitamin D 
may have beneficial effects on serum FPG, HbA1c and insulin resistance among 
individuals with type 2 diabetes (47). In a recent meta-analysis of 24 controlled trials, 
Mirhosseini et al. (47) indicated insufficient evidence regarding the improvement in 
glycemic control with vitamin D supplementation might be due to insufficient dose of 
vitamin D (< 4000 IU/day), short duration of supplementation, high BMI and small study 
sample size (47). Obesity has inverse effects on serum 25(OH)D (48). As vitamin D is a 
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fat-soluble vitamin, it can get trapped in the fat tissue and become less biologically 
available to the body. Vimaleswaran et al. (49) reported a 1.15% decrease in serum 
25(OH)D3 for each kg/m² increase in BMI. It is suggested that obese people with 
insufficient vitamin D level should take 2-3 times higher doses of vitamin D to replenish.  
A recent prospective observational cohort study found a significant decrease in 
HbA1c with vitamin D3 supplementation for 9 months (50). This study was conducted 
among 1000 individuals with type 1 and type 2 diabetes. The supplementation dosage in 
this study was not revealed in the article (50). Although we cannot compare this study 
with ours based on the vitamin D supplementation dosage, their extended study duration 
may suggest vitamin D supplementation for longer periods than 6 months may have 
beneficial effects on glycemic control outcomes in individuals with diabetes.  
In a community-based longitudinal study among 1018 individuals without type 2 
diabetes, the effect of vitamin D supplementation alone, and vitamin supplementation in 
combination with other nutrients on glycemic status was assessed (51). First group (n 
=223) received daily supplementation of 1000-20,000 IU/day vitamin D3, as needed to 
achieve the target serum 25(OH)D3 level, and group 2 (n = 790) was assigned to 1000-
20,000 IU/day with vitamin D3 and additional supplements (omega-3 fatty acids, vitamin 
C, magnesium, caprylic acid, PolyGlycopleX and probiotics). The results of this study 
showed significant increase in serum 25(OH)D3 in both groups over the period of 12 
months. HbA1c and CRP were significantly reduced only among group 2, after 12 
months of supplementation. Larger decrease in HbA1c and CRP levels were associated 
with higher 25(OH)D3 level after 12 months. The results of this study suggested that 
participants in group 2 were less likely to develop prediabetes/diabetes, compared to 
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participants in group 1 (8% vs. 16%). Furthermore, 44% of subjects with prediabetes in 
group 2 improved to normoglycemic after 12 months, compared to 8% in group 1. This 
study concluded that vitamin D supplementation in combination with other nutrients may 
have beneficial effects on glycemic control and reduce the risk of diabetogenesis (51).  
Conclusion 
Daily supplementation with higher doses of vitamin D3 (>4000 IU) may have 
beneficial effects on health status of individuals with type 2 diabetes. GA% may be a 
more sensitive biomarker for oxidative/glycemic changes in individuals with type 2 
diabetes and hypovitaminosis D. The limitations of the study included small sample size, 
lack of a control group, shorter duration of the study, and utilization of frozen serum 
samples to measure GA. The strengths of the study were its novelty to assess the effect of 
vitamin D3 supplementation on less studied biomarkers of glycemic/oxidative status and 
the ability to compare two different doses of vitamin D3 supplementation. Larger studies 
with longer durations among different racial and ethnic groups with and without diabetes 
may help to confirm the benefits of vitamin D3 supplementation on oxidative and 
glycemic health outcomes.  
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Table 1. Participants`s characteristics at baseline  
Variable 
Mean ± SD 
(N= 65) 
Age (years) 
Gender n (%) 
       Female 
       Male 
Dosage n (%) 
   4000 IU                                                                                                         
   6000 IU 
54.52 ± 7.86 
 
40 (62 ) 
25 (38) 
                         
44 (68) 
21 (32) 
BMI (kg/m2) 33.57 ± 6.5 
Skin sun exposure score 4.2 ± 4.02 
25(OH)D3 (ng/mL) 22.4 ± 6.77 
FPG (mg/dL) 186.478 ± 79.93 
HbA1c (%) 8.41 ± 2.31 
Insulin (mg/dL) 12.63 ± 11.56 
CRP (mg/dL) 8.06 ± 10.81 
GA (mg/mL) 1.51 ± 0.44 
ALB (mg/mL) 32.84 ± 05.69 
GA% 4.69 ± 1.7 
Data are mean ± (SD) or %. BMI = Body mass index. HbA1c = 
glycated hemoglobin. CRP = C-reactive protein. GA = glycated 
albumin. ALB = serum total albumin. GA% = (GA/ALB)%. 
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Table 2. Mixed model comparisons of repeated measures at baseline, after 3 months and 
after 6 months without adjustment for covariates.  
Variable Mean ± SE 
(N = 65) 
P-value 
ALB (mg/mL) 
Baseline 
3 months 
             6 months 
  
33.08 ± 0.74 
36.67 ± 0.96 
35.52 ± 0.89 
  
  
*0.003 
*0.031 
GA% 
Baseline 
3 months 
6 months 
  
4.58 ± 0.19 
4.07 ± 0.14 
4.43 ± 0.16 
  
  
*0.015 
*0.039 
25(OH)D3 (ng/mL) 
Baseline 
3 months 
6 months 
  
22.49 ± 0.897 
41.96 ± 1.71 
41.46 ± 1.91 
  
  
*<0.001 
*<0.001 
Data represented by mean ± standard error. * P-values are from multiple comparisons 
with Bonferroni correction. Statistically significance from baseline. P<0.05 is considered 
significant. Time and dosage interactions were not significant for any of the variables 
included in table 2. GA=glycated albumin. GA% = (GA/ALB)%. 
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Table 3. Mixed model comparisons of repeated measures at baseline, after 3 months and 
after 6 months with adjustment for covariates. 
                           Mean ± SD 
          (N = 65) 
P-value 
ALB (mg/mL) 
Baseline 
3 months 
6 months 
 
33.02 ± 0.74 
36.51 ± 0.96 
35.42 ± 0.87 
 
 
0.004* 
0.046* 
GA% 
Baseline 
3 months 
6 months 
 
4.58 ± 0.19 
4.09 ± 0.141 
4.41 ± 0.173 
 
 
0.018* 
        0.471 
Data represented by mean ± standard error. *P-values are from multiple comparisons 
with Bonferroni correction. Statistically significance from baseline. P<0.05 is considered 
significant. GA=glycated albumin. ALB=serum total albumin. GA%=(GA/ALB)%. Time 
and dosage interactions were not significant for ALB and GA%. Mixed model analysis 
was adjusted for age, gender, BMI, sun exposure, fasting plasma glucose, insulin and 
CRP. 
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CHAPTER V: SUMMARY AND CONCLUSIONS 
    
The results of the present study showed that pro-inflammatory dietary intakes 
may be associated with increased risk of hypo-insulinemia and incidence of higher SBP 
among individuals with type 2 diabetes and vitamin D deficiency/insufficiency. 
Furthermore, we showed daily oral supplementation with higher doses of vitamin D, 
4000 IU and 6000 IU/day compared to the recommended dose of 600 IU/day, for 6 
months may improve oxidative stress status among a group of individuals with type 2 
diabetes and vitamin D deficiency/insufficiency. Serum 8-OHdG may be a predictive 
biomarker of DNA/RNA damage among individuals with type 2 diabetes. Our results 
showed no improvements in 8-OHDdG after 3 months of supplementation with vitamin 
D among individuals with vitamin D deficiency/insufficiency. This may suggest that 
longer supplementation durations than 3 months should be considered for interventions 
among individuals with vitamin D insufficiency/deficiency. We did not find significant 
changes in sun exposure during the 6 month period of this study. This study suggests 
daily supplementation with higher doses of vitamin D3, 4000 IU and 6000 IU/day 
compared to the recommended dose of 600 IU/day, may have further beneficial effects on 
health status of individuals with type 2 diabetes. Vitamin D supplementation for 3 months 
may decrease the GA% among individuals with type 2. This study showed that GA% 
change pattern followed 25OHD change pattern inversely: As 25OHD increased from 
baseline to 3 months, GA% decreased. When 25OHD remained unchanged from 3 
months to 6 months, GA% did not change significantly. Based on the present study`s 
results, GA% may be a more sensitive biomarker for oxidative/glycemic changes in 
individuals with type 2 diabetes and hypovitaminosis D.  
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In summary, daily oral supplementation with higher doses of vitamin D, 4000 IU 
and 6000 IU/day compared to the recommended dose of 600 IU/day, and anti-
inflammatory dietary intakes may have beneficial effects on health status of individuals 
with type 2 diabetes and vitamin D deficiency/insufficiency. The results of this study may 
serve as a basis for the future nutrition interventions to improve the dietary inflammatory 
intake and health status of individuals with type 2 diabetes. Larger studies with longer 
durations among different racial and ethnic groups with and without diabetes may help to 
confirm the benefits of vitamin D3 supplementation and anti-inflammatory dietary 
patterns on oxidative and glycemic health outcomes.  
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Appendix 3: Skin Color and Anthropometrics Record Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4: Demographic Questionnaire 
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Appendix 5: Compliance and Adverse Events Form 
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